1996 Cancer in Alaska Cancer Incidence and Mortality

State of Alaska Tony Knowles, Governor

Alaska Department of Health and Social Services Karen Perdue, Commissioner

> *Division of Public Health Peter Nakamura, MD, MPH, Director*

.

> *Alaska Cancer Registry Revised April 2000*

Cancer Incidence and Mortality in Alaska, 1996

Annual Report of the Alaska Cancer Registry Revised April 2000

Prepared by:

John P. Middaugh, MD Jeanne Roche, RN, MPH, CTR Michele Czajkowski, MS, CTR Lynne McCarter, BAA Section of Epidemiology

Acknowledgments

National Program of Cancer Registries Centers for Disease Control and Prevention

Special Acknowledgment

The authors thank the numerous individuals from the wide variety of health care facilities who reported cancer data in Alaska; especially the physicians, medical records personnel and cancer registrars, whose participation and cooperation have made the Alaska Cancer Registry a reality at last. The authors wish also to thank Malcolm C. Pike, PhD, Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center, University of Southern California School of Medicine for sharing his expertise and providing technical assistance to the Alaska Cancer Registry.

For more information or additional copies of this report contact:

Alaska Cancer Registry Section of Epidemiology 3601 C Street, Ste 540 P.O. Box 240249 Anchorage, AK 99524-0249 (907) 269-8000

Or visit our Website: www.epi.hss.state.ak.us

This work was funded in part by the Centers for Disease Control and Prevention, Cooperative Agreement # U75/CCU010706-04

Highlights

The Alaska Cancer Registry is pleased to release its *Revised 1996 Annual Report* which provides statewide cancer statistics for both incidence and mortality. Highlights from findings from this report are summarized below:

- During 1996, there were 1,600 invasive cancers diagnosed among Alaska residents.
- The incidence rate for all cancers in Alaska was 8% higher for males than females.
- The five most commonly diagnosed cancers among Alaska men were cancers of the prostate (24% of total incident cases), lung (18%), colorectal (11%), urinary bladder (5%) and non-Hodgkin's lymphoma (4%).
- The five most commonly diagnosed cancers among Alaska women were cancers of the breast (32% of total incident cases), lung (13%), colorectal (9%), thyroid (5%) and uterus (4%).
- Of all the cancers diagnosed in 1996, 82% were Alaskans 45 years of age or older.
- A total of 648 persons in Alaska died from cancer in 1996.
- The mortality rate for all cancers was 30% higher for males than females.
- For both sexes combined, the most common cancer deaths in Alaska were lung (184 deaths), colorectal (62), breast (53), pancreas (35) and stomach (29). These accounted for 56% of total cancer deaths; lung cancer alone accounted for 28%.
- Among Alaska males, the five leading cancer deaths were lung (31% of total cancer deaths), colorectal (9%), stomach (6%), prostate (5%) and leukemias (4%).
- Among Alaska females, the five leading cancer deaths were lung (25% of total deaths), breast (18%), colorectal (9%), pancreas (6%) and ovary (4%).
- Of the total cancer deaths, 56% were of Alaskans 65 years of age or older.

Table of Contents

Introduction	1
What is Cancer?	
The Alaska Cancer Registry	3
Data Definitions	6
Section I	

Percent of Cancer Cases and Deaths by Site	9

Section II

Primary Sites

a.	All Cancers Combined	19
b.	Bladder	22
c.	Brain and Other Nervous System	23
	Breast (female)	
	Cervix	
	Colorectal	
	Hodgkin's Disease	
	Kidney and Renal Pelvis	
	Leukemias	
j.	Lung and Bronchus	30
k.	Melanomas of the Skin	31
m.	Non-Hodgkin's Lymphomas Oral Cavity and Pharynx	33
n.	Ovary	34
0.	Pancreas	35
p.	Prostate	36
r.	Stomach Thyroid	38
S.	Uterus	39

Section III

Table 1.	Age Distribution of Total Invasive Cancers	43
	Total Cancer Incidence and Mortality by Site	
	Male Cancer Incidence and Mortality by Site	
	Female Cancer Incidence and Mortality by Site	

Appendices

I.	Code Classification Used for Grouping Sites of Cancer	63
II.	1970 U.S. Standard Million Population	67
	1996 Alaska Population	
	1	

Introduction

What Is Cancer?

Cancer is a group of many related diseases. All forms of cancer involve out-of-control growth and spread of cells.

The human body is made up of billions of cells. Groups of cells perform a specific function. Normally body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells divide more rapidly until the person becomes an adult. After that, normal cells of most tissues divide only to replace worn-out or dying cells and to repair injuries.

Cancer cells, however, continue to grow and divide, and can spread to other parts of the body. These cells accumulate and form *tumors* (lumps) that compress, invade, and destroy normal tissue. If cells break away from such a tumor, they can travel through the bloodstream or the lymph system to other areas of the body. There, they may settle and form "colony" tumors. In their new location, the cancer cells continue growing. The spread of a tumor to a new site is called *metastasis*. When cancer spreads, though, it is still named after the body part where it started. For example, if prostate cancer spreads to the bones, it is still prostate cancer, and if breast cancer spreads to the lungs it is still called breast cancer.¹

Leukemia, a form of cancer, does not usually form a tumor. Instead, these cancer cells involve the blood and blood-forming organs (bone marrow, lymphatic system, and spleen), and circulate through other tissues where they can accumulate.¹

It is important to realize that not all tumors are cancerous. Benign tumors do not metastasize and, with very rare exceptions, are not life-threatening.¹

Cancer is classified by the part of the body in which it began, and by its appearance under a microscope. Different types of cancer vary in their rates of growth, patterns of spread, and responses to different types of treatment. That's why people with cancer need treatment that is aimed at their specific form of the disease.¹

Who Is At Risk?

Everyone. In America, half of all men and one-third of all women will develop cancer during their lifetimes. Today, millions of people are living with cancer or have been cured of the disease. The sooner a cancer is found, and the sooner treatment begins, the better the person's chances are of a cure.

It has long been estimated that approximately 70% of all cancers are due to environmental factors. "Environmental" is broadly defined as all those external factors that affect us, and includes tobacco, viruses, radiation, individual exposures from sexual or occupational practices, diet and exercise, etc., and not just what is thought of as the environmental pollution of air, water, and food.

Tobacco is the greatest risk factor for all cancers combined and is the single leading preventable cause of cancer. Excessive alcohol consumption, particularly coupled with tobacco use, and failure to eat sufficient fresh fruits, vegetables and whole grains contribute to one-third of all cancers. Reduction of these risk factors can be controlled by individual behavioral choices.

Research indicates that genes play a role, but the currently known genetic "markers" account for only a very small proportion of cancers. Future research may well identify additional genes that predispose toward cancer.

Although there are certain specific childhood cancers that have an expected early age peak and then are rarely seen in the rest of the population, the occurrence of cancer generally increases with age and the majority of cancers occur among adults middle-aged or older. The term *lifetime risk* is the probability that an individual, over the course of a lifetime, will develop cancer or die from it. In the U.S., men have a 1 in 2 lifetime risk of developing cancer, and for women the risk is 1 in 3.² The American Cancer Society (ACS) has published updates on probability of developing cancer; the most recent is described below:

1//# 1//+					
		Birth to 39	40 to 59	60-79	Birth to Death
All Sites*	Male	1.68 (1 in 60)	8.23 (1 in 12)	36.69 (1 in 3)	46.64 (1 in 2)
	Female	1.94 (1 in 52)	9.05 (1 in 11)	22.21 (1 in 5)	38.00 (1 in 3)
Breast	Female	0.44 (1 in 227)	3.94 (1 in 25)	6.89 (1 in 15)	12.52 (1 in 8)
Colorectal	Male	0.06 (1 in 1,667)	0.88 (1 in 114)	4.19 (1 in 24)	5.88 (1 in 17)
	Female	0.05 (1 in 2,000)	0.68 (1 in 147)	3.18 (1 in 31)	5.72 (1 in 17)
Lung	Male	0.04 (1 in 2,500)	1.39 (1 in 72)	6.69 (1 in 15)	8.43 (1 in 12)
	Female	0.03 (1 in 3,333)	1.00 (1 in 100)	3.88 (1 in 26)	5.55 (1 in 18)
Prostate	Male	Less than 1 in 10,000	1.74 (1 in 57)	16.40 (1 in 6)	18.85 (1 in 5)

Percentage of Population (Probability) Developing Invasive Cancers at Certain Ages by Sex, U.S., 1992-1994²

Reprinted with permission of Amercian Cancer Society, Inc.

*Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.

Data source: NCI Surveillance, Epidemiology, and End Results Program, 1997.

1998, American Cancer Society, Inc.

Sometimes when a family member or friend is diagnosed with cancer, the tragedy makes us more aware of others in our community with cancer and we begin to be concerned that there may be an unusually large number of cancer cases in a certain area. Sometimes this may be the case, but not often. There are a certain number of cancers that are expected to occur in any U.S. population. These are of the predominant, or leading cancers in the U.S. The rank order may vary but they will almost always be found in each community/state among the top cancer sites, and include: lung, breast, colorectal and prostate. The American Cancer Society has provided a methodology for communities to estimate their potential cancer cases/deaths.

How to Estimate Cancer Statistics Locally, 1	<u>998</u> ²				
	Multiply co	mmunity po	pulation by:		
To obtain the estimated number of		Female	Colon &		
	All Sites	Breast*	Rectum	Lung	Prostate*
New cancer cases [per year] ⁺	0.0046	0.0013	0.0005	0.0006	0.0014
Cancer deaths [per year]+	0.0021	0.0003	0.0002	0.0006	0.0003
People who will eventually develop cancer	0.4232	0.1252	0.0580	0.0699	0.1885
People who will eventually die of cancer	0.2224	0.0346	0.0255	0.0574	0.0364

+Added for Clarity

Reprinted with permission of American Cancer Society, Inc.

*For female breast and prostate cancer multiply by female and male population respectively. American Cancer Society, Surveillance Research, 1998. Data Source: NCI Surveillance, Epidemiology, and End Results Program, 1997. 1998, American Cancer Society, Inc.

1. American Cancer Society Web Page, <u>www.cancer.org</u>, What is Cancer?

2. Cancer Facts & Figures 1998. American Cancer Society, Inc. 1998.

The Alaska Cancer Registry

Since the publication of *1996 Cancer in Alaska*, the first annual report of the Alaska Cancer Registry, two audits of the 1996 data have occurred. The North American Association of Central Cancer Registries (NAACCR) was contracted by CDC to assess the Alaska Cancer Registry's case completeness and data quality. NAACCR randomly sampled six hospitals and completed their audit September 1999. The Alaska Cancer Registry completed its own audit of the remaining hospitals in December 1999. Collectively, these two audits identified 105 cases that were not reported by any other source, and therefore, were not counted in the 1996 report. The difference in some cancer site counts, in comparison to the upcoming 1997 data, warranted issuing a revised 1996 report to prevent potential concerns when comparing the two years of data. Additionally, the 1996 Alaska population was revised in May 1999. This has had an effect of increasing certain cancer mortality rates although the number of deaths remain unchanged.

Purpose of the Registry

The Alaska Cancer Registry is a cancer surveillance system that is population-based. The Registry collects a wide variety of information to determine cancer incidence, mortality, treatment and survival. The data is used to:

- determine the incidence of cancer in the state of Alaska with respect to geographic and demographic characteristics
- monitor trends over time for unusual patterns
- monitor early detection, evaluate the effectiveness of cancer control programs and identify areas in need of public health interventions
- determine how Alaska compares with the rest of the Nation
- provide a database and serve as a resource for health planners, medical professionals, researchers and others concerned about cancer.

History of the Registry

In 1992, as a result of the enactment of Public Law 102-515, the Cancer Registries Amendment Act, the National Program of Cancer Registries (NPCR) was established with the U.S. Centers for Disease Control and Prevention (CDC) as the lead agency. This federal legislation authorized states and territories to enhance existing cancer registries; plan and implement registries where they did not exist; develop model legislation and regulations for states to enhance viability of registry operations; set standards for completeness, timeliness and quality of data; and, provide training. In October 1994, the Alaska Division of Public Health, Section of Epidemiology, received CDC funds to plan and implement a State cancer registry.

On January 19, 1996, the Alaska Administrative Code (7 AAC 27.011) established reporting requirements for a statewide cancer registry. The regulations require all hospitals, health care facilities and health care practitioners screening, diagnosing or providing treatment for cancer patients diagnosed on or after January 1, 1996 to report this information to the Alaska Division of Public Health, Section of Epidemiology.

Data Collection

The Registry collects data on each newly diagnosed cancer case. Any facility diagnosing or treating a cancer patient is required to report specific data to the Registry if the patient is diagnosed on or after January 1, 1996. In an effort to streamline the administrative burden of a new reporting requirement, hospitals have been the reporting focus. While physicians are required to report their newly diagnosed cancer patients, this can largely be accomplished through hospital reporting. To help ensure that Alaska residents diagnosed or treated out of state are reported, the Registry has interstate agreements with a limited number of states that facilitate case reporting by their state registries to the Alaska Cancer Registry.

Only 29% of Alaska's hospitals have cancer registries where many different types of hospital records are actively screened to ensure every cancer case seen in the facility is identified. Hospital-based registries require specially trained staff for case abstracting and collect more detailed information for their internal use than is required at the State level. In non-registry hospitals, the health information management staff usually utilizes the same type of hospital records to identify cancer cases and report them to the Registry where they are reviewed and abstracted. The Registry staff is available for technical assistance and limited training.

One of the strengths of the Registry is its use of multiple sources for identification of diagnosed cases. This includes reports from laboratories, clinics, physician offices, screening programs and other cancer treating facilities. All reports are matched electronically to avoid duplication of case counts and to obtain the most complete information on a given case.

The Registry collects information on all in situ and invasive cancers (those with behavior codes 2 or 3 in the *International Classification of Disease for Oncology*, 2nd Ed.). There are two types of cancer that are exceptions:

- Carcinoma in situ of the cervix
- Basal and squamous cell skin cancers (unless these are at a mucocutaneous junction or external genital area). These cancers are exempt from reporting because they are rarely fatal and usually do not require hospitalization.

The specific information required to be reported on each cancer case includes demographic data (date of birth, sex, ethnicity, race, residence, etc.) and information on each primary tumor - including site, histology, staging and first course of cancer-directed treatment.

Data Quality

The Alaska Cancer Registry is a member of the North American Association of Central Cancer Registries (NAACCR) which sets standards for data definition, quality and completeness of reporting. The Registry staff work with reporting facilities to ensure cancer cases are reported on time and with high quality data. All abstracts received are manually checked for completeness and accuracy. Computerized edits are run on all submitted data before entering the central database. These edits check for valid codes and omission of required information, which must be resolved before data can be used for analysis. Computerized edits include checks for duplicate cases and other errors or inconsistencies, such as unlikely sex/ site, site/morphology, or site/age combinations. Inter-record comparisons are performed for patients having more than one primary cancer so that demographic data match.

Three indicators commonly measure the quality of cancer reporting: the proportion of cases reported by death certificate only, the percentage of cases histologically confirmed and the proportion of cases with nonspecific diagnoses. The number of "death certificate only" cases gives an indication of the completeness of reporting. The number of histologically confirmed cases and the number with nonspecific diagnoses indicate the accuracy of diagnostic information.

Confidentiality of Data

Alaska law demands strict confidentiality and the protection of the identity of both cancer patients and sources reporting to the Registry. An additional law protects facilities and physicians from any liability for their reporting to the registry program. Registry personnel sign a confidentiality policy and are subject to penalty if they disclose confidential information. Access to the Registry office and all Registry data is restricted. Any research study involving data with unique identifiers must be reviewed by an Institutional Review Board, which protects rights to privacy and informed consent, with final approval resting with the Alaska Department of Health & Social Services.

Data Definitions

Incidence Data

An incident case is defined as a <u>newly diagnosed</u> primary cancer. A primary cancer, or site, is the cancer of origin, as opposed to a cancer that has spread, or metastasized, from another site. Since individuals can have more than one primary cancer, diagnosed either sequentially or at the same time, the number of incident cases may be greater than the number of persons who were diagnosed with cancer.

This report includes all cancer cases newly diagnosed in 1996 and reported to the Alaska Cancer Registry as of February 8, 2000. Only Alaska residents are included in the incidence data. Incidence data are presented as the number of cases, age-adjusted incidence rates, age-specific rates, and percent frequencies.

The Alaska Cancer Registry follows standard protocols so that its incidence rates can be compared with those from other registries and the U.S. These include the following:

- Most neoplasms are grouped by the organ where they arise. The organ of origination is called the primary site. Appendix I shows the groupings of codes for systems, sites, and sub-sites.
- Only invasive neoplasms, those that have penetrated the basement membrane, are included. The sole exception is cancer of the bladder, for which in situ cases are included with invasive cases. Some cancers are considered systemic, or the organs actually have no basement membrane tissue to penetrate. These cancers are indicated, where reviewed, with in situ as not applicable (n/a).
- Basal cell and squamous cell carcinomas of the skin are excluded unless they occur at a mucocutaneous juncture or external genital areas. In these instances, they are considered cancers of the organs where they are located, not skin cancers.
- Neoplasms of the lymphatic, hematopoietic, and reticuloendothelial systems are grouped by their histology (e.g., leukemia, lymphoma), not by the anatomical sites where they occur. For example, lymphomas of the breast are grouped with non-Hodgkin's lymphomas rather than with breast cancers.

Cases that are excluded from the incidence rates and all site totals presented in Sections II and III include the following:

- in situ cases (104 cases excludes bladder)
- cases with unknown age (0 cases)
- cases with unknown gender (0 cases)

Mortality Data

Mortality data are presented as number of deaths and age-adjusted rates. The most recent U.S. rates are presented for comparison. Appendix I describes the anatomical site groupings of codes from the *International Classification of Diseases*, 9th Revision, which is used for death certificates.

Information on Alaska residents who died from cancer during 1996 was obtained from the Division of Public Health, Bureau of Vital Statistics. Deaths are attributed to cancer only if the underlying cause of death is listed as cancer. Only Alaska residents are included in mortality data.

Age-Adjusted Rates

Overall, the rates presented are age-adjusted (as indicated). Age-adjustment is a statistical process, which allow communities/states with different age structures to be compared. Age adjustment removes the influence of the differences in age distributions that occur from one population to another. Since the risk of developing cancer is strongly associated with age, a geographic area with a high proportion of elderly residents could not be accurately compared with a younger-age populated area unless rates were adjusted to a standard reference population.

A community with an older population will almost always have more cancer than one with a younger population. This will be true even if individuals of the same age in the two communities have the same risk of developing cancer. This is called "confounding" and it occurs when the measurement of the association between the exposure and the disease is mixed up with some extraneous factor (a confounding variable). Age-adjustment is an internationally approved statistical method to remove confounding caused by age.

The incidence rates presented have been adjusted by the direct method to the age distribution of the 1970 U.S. population (Appendix II). They can be compared directly with each other or with any published rates that have been adjusted to the same population and are expressed per 100,000 persons.

Age-Specific Rates

Age-specific rates are calculated by dividing the number of cases for a given age-group by the total population of that agegroup. These are expressed as a rate per 100,000 persons and show the variation in cancer incidence by age group for males, females and the total population as appropriate.

U.S. Rates

Comparison U.S. incidence rates are "national" rates which are age-adjusted rates calculated from a sample population based on the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. The SEER program currently includes five state registries (Connecticut, Hawaii, Iowa, New Mexico, Utah) and six metropolitan areas (Detroit, Atlanta, San Francisco/Oakland, Seattle/Puget Sound, Los Angeles, and San Jose-Monterey area). These registries represent about 13.9% of the U.S. population. U.S. rates presented are age-adjusted and are the most current published rates.

Mortality rates for the U.S. are based on data from the National Center for Health Statistics, to which all states submit death certificate information. The U.S. mortality rates presented are also age-adjusted to the 1970 U.S. population.

Alaska Population Estimates

The computation of incidence, mortality and age-specific rates requires population determination by age, sex, and race. This information was obtained from the Alaska Department of Labor for 1996, and is the same population data used by the Alaska Bureau of Vital Statistics (Appendix III).

Race

Information on race is missing on 2.3% (n=37) of the cases reported to the Registry. African-Americans and Asian/Pacific Islanders each represented only 20 newly diagnosed cancer cases for 1996. Alaska Natives represented a total of 20% of cases reported, which is expected given the percent of the total population. However, because the analysis of incidence by cancer site by race left Alaska Natives with very small numbers, too few and unstable to represent by rates, no race data is presented in this Report.

Borough/Census Area

The borough/census areas described are Alaska's current designated census areas.

No rates are provided for these geographic locations. Clearly, the numbers of total cancers or specific cancer types are very small for the majority of borough/census areas. The main urban sites, where the majority of Alaska's population resides, have the greater number of case counts. It is likely the Alaska Cancer Registry will not have the power to describe any geographic variation until at least three calendar years of data have been fully reported.

Small Populations and Few Events

Data based on small populations and a small number of events require careful analysis. Alaska's population is divided into many small groups (census areas) where variation is expected and may be attributed to chance. Rates that are based on fewer than five cases are considered unstable because they have a large standard error. For this reason, in Sections II and III, a "n/c" indicates a rate is not calculated for cases that are less than five.

Confidence Intervals

Confidence intervals for directly standardized rates were calculated for incidence and mortality based on the Fay/Feuer method.¹


A confidence interval is a range around a measurement that conveys how precise the measurement is. Because random variation can change the number of particular cases of cancer diagnosed each year we cannot exactly specify the long-term incidence of a type of cancer for any particular year. For example, perhaps 2 cases of stomach cancer were diagnosed in early January 1997 instead of last December 1996 because the physicians (or the patients) were on vacation at the end of 1996. The incidence of stomach cancer in 1996 appears lower than it might have been otherwise. If the two stomach cancers were two of only four for the entire year, then attributing those cases to 1997 instead of 1996 more drastically affects the estimate of stomach cancer incidence than if those cases were two of 40 stomach cancers for the year.

Confidence intervals provide a method to quantify how accurate we believe the estimate to be (which as illustrated above, depends on the number of cases observed). A 95% confidence interval around an estimate specifies a range in which we believe the true estimate lies, with 95% probability.

¹ Fay MP and Feur EJ. Confidence Intervals for directly standardized rates: a method based on the gamma distribution. Statistics in Medicine, vol. 16, 791-801 (1997).


Section I

Percent of Cancer Cases by Site 1996 Invasive Cancer Cases (n=1600) - Alaska Residents




of Cases

Percent of Cancer Deaths by Site 1996 Cancer Deaths (n=648) - Alaska Residents




Percent of Cancer Cases by Site 1996 Male Invasive Cancer Cases (n=782) - Alaska Residents




of Cases

Percent of Cancer Deaths by Site 1996 Male Cancer Deaths (n=354) - Alaska Residents




Percent of Cancer Cases by Site 1996 Female Invasive Cancer Cases (n=818) - Alaska Residents



of Cases

Percent of Cancer Deaths by Site 1996 Female Cancer Deaths (n=294) - Alaska Residents



Section II

All Cancers Combined

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C00.0 - C80.9, and including all morphology codes except those indicating benign neoplasms. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 140.0 - 208.9.

1996 Alaska Residents

Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
In situ cancer+	16	88	104
Invasive cancer	782	818	1600
Incidence rate*	406.1	375.6	386.8
1995 U.S. rate*	460.1	344.3	392.0
+Excludes in situ of bladder			
*Excludes in situ cases except bladder			
<u>Mortality</u>	Male	<u>Female</u>	<u>Total</u>
Deaths	354	294	648
Mortality rate	204.7	155.1	177.8
1995 U.S. rate	210.6	140.8	169.1

Invasive Cancer by Borough/Census Area

Aleutians East	3	Kenai Peninsula	149	Skagway-Hoonah-Angoon	16
Aleutians West	11	Ketchikan Gateway	47	Southeast Fairbanks	19
Anchorage	640	Kodiak Island	47	Valdez-Cordova	35
Bethel	18	Lake and Peninsula	3	Wade Hampton	14
Bristol Bay	3	Matanuska-Susitna	149	Wrangell-Petersburg	26
Denali	6	Nome	17	Yakutat	4
Dillingham	13	North Slope	14	Yukon-Koyukuk	17
Fairbanks North Star	189	Northwest Arctic	13	Unknown	6
Haines	7	Prince of Wales-Outer Ketchikan	12		
Juneau	93	Sitka	29		


Stage at Diagnosis**

<u>Alaska (n = 1600)</u>


**Stage at Diagnosis is unique for each primary site and, therefore, cannot be applied to "All Cancers Combined".

All Cancers Combined

Age-Specific Mortality Rates Alaska (1996) and U.S. (1995)




All Cancers Combined



Age-Specific Incidence Rates Alaska (1996) and U.S. (1995)


All Cancers Combined

Age-Specific Mortality Rates by Sex Alaska (1996) and U.S. (1995)



All Cancers Combined

Age-Specific Incidence Rates by Sex Alaska (1996) and U.S. (1995)



Age group

Bladder*


Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C67.0 - C67.9, and excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 188.0 - 188.9.

1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

Incidence	<u>Male</u>	<u>Female</u>	<u>Total</u>
In situ and invasive cancer	41	19	60
Incidence rate	23.6	9.5	16.0
1995 U.S. rate	28.3	7.7	16.5
*Urinary Bladder (includes in situ)			
<u>Mortality</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
Deaths	11	1	12
Mortality rate	8.0	n/c **	4.0
1995 U.S. rate	5.5	1.6	3.2
**n/c = rate not calculated if n<5			

Bladder Cancer by Borough/Census Area

	•	0		
Aleutians East	0	Kenai Peninsula	4	Skagway-Hoonah-Angoon
Aleutians West	0	Ketchikan Gateway	3	Southeast Fairbanks
Anchorage	20	Kodiak Island	1	Valdez-Cordova
Bethel	0	Lake and Peninsula	0	Wade Hampton
Bristol Bay	1	Matanuska-Susitna	7	Wrangell-Petersburg
Denali	1	Nome	0	Yakutat
Dillingham	0	North Slope	0	Yukon-Koyukuk
Fairbanks North Star	12	Northwest Arctic	1	Unknown
Haines	0	Prince of Wales-Outer Ketchikan	0	
Juneau	6	Sitka	0	



Brain and other Nervous System

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C70.0 - C70.9, C71.0 - C71.9 and C72.0 - C72.9, excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 191.0 - 191.9, 192.0 - 192.3 and 192.8 - 192.9.

1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	Male	<u>Female</u>	<u>Total</u>
In situ cancer	0	0	0
Invasive cancer	18	9	27
Incidence rate	6.2	3.3	4.7
1995 U.S. rate*	7.0	4.7	5.8
*Excludes in situ cases			
Mortality	<u>Male</u>	<u>Female</u>	<u>Total</u>
Deaths	17	6	23
Mortality rate	5.8	2.4	4.2
1995 U.S. rate	4.9	3.4	4.1


Brain Cancer by Borough/Census Area

Aleutians East	0	Kenai Peninsula	3	Skagway-Hoonah-Angoon	0
Aleutians West	0	Ketchikan Gateway	1	Southeast Fairbanks	0
Anchorage	9	Kodiak Island	1	Valdez-Cordova	0
Bethel	0	Lake and Peninsula	0	Wade Hampton	0
Bristol Bay	0	Matanuska-Susitna	4	Wrangell-Petersburg	0
Denali	0	Nome	0	Yakutat	0
Dillingham	0	North Slope	1	Yukon-Koyukuk	0
Fairbanks North Star	4	Northwest Arctic	0	Unknown	1
Haines	0	Prince of Wales-Outer Ketchikan	0		
Juneau	2	Sitka	1		

Alaska (n=27)

Stage at Diagnosis

U.S.



Breast (female)

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C50.0 - C50.9, and excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 174.0 - 174.9.

1996 Alaska Residents


Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	<u>Female</u>	
In situ cancer	66	
Invasive cancer	261	
Incidence rate*	109.3	
1995 U.S. rate*	111.3	
*Excludes in situ cases		
<u>Mortality</u>	<u>Female</u>	
Deaths	53	
Mortality rate	24.1	
1995 U.Š. rate	25.2	

Invasive Breast Cancer by Borough/Census Area

Aleutians East	0	Kenai Peninsula	19	Skagway-Hoonah-Angoon	5
Aleutians West	0	Ketchikan Gateway	10	Southeast Fairbanks	0
Anchorage	105	Kodiak Island	11	Valdez-Cordova	10
Bethel	3	Lake and Peninsula	1	Wade Hampton	3
Bristol Bay	0	Matanuska-Susitna	28	Wrangell-Petersburg	8
Denali	2	Nome	1	Yakutat	1
Dillingham	0	North Slope	3	Yukon-Koyukuk	0
Fairbanks North Star	28	Northwest Arctic	1	Unknown	0
Haines	0	Prince of Wales-Outer Ketchikan	1		
Juneau	19	Sitka	2		

Stage at Diagnosis



Cervix

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C53.0 - C53.9, and excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 180.0 - 180.9.


1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	<u>Female</u>	
Invasive cancer	26	
Incidence rate*	8.9	
1995 U.S. rate*	7.4	
*Excludes in situ cases		
<u>Mortality</u>	<u>Female</u>	
Deaths	6	
Mortality rate	2.6	
1995 U.S. rate	2.7	

Cervical Cancer by Borough/Census Area

Aleutians East	0	Kenai Peninsula	3	Skagway-Hoonah-Angoon	0
Aleutians West	0	Ketchikan Gateway	0	Southeast Fairbanks	0
Anchorage	12	Kodiak Island	0	Valdez-Cordova	1
Bethel	0	Lake and Peninsula	0	Wade Hampton	0
Bristol Bay	0	Matanuska-Susitna	2	Wrangell-Petersburg	0
Denali	0	Nome	0	Yakutat	0
Dillingham	0	North Slope	0	Yukon-Koyukuk	0
Fairbanks North Star	6	Northwest Arctic	0	Unknown	0
Haines	0	Prince of Wales-Outer Ketchikan	1		
Juneau	1	Sitka	0		





Colorectal

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C18.0 - C18.9, C19.9, C20.9 and C26.0, and excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 153.0 - 153.9, 154.0 - 154.1 and 159.0.


1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
In situ cancer	7	3	10
Invasive cancer	88	78	166
Incidence rate*	48.1	41.1	43.9
1995 U.S. rate*	50.3	36.9	42.7
*Excludes in situ cases			
Mortality	<u>Male</u>	<u>Female</u>	<u>Total</u>
Deaths	34	28	62
Mortality rate	21.5	16.5	18.8
1995 U.Š. rate	21.2	14.5	17.4

Invasive Colorectal Cancer by Borough/Census Area

Aleutians East	0	Kenai Peninsula	9	Skagway-Hoonah-Angoon	0
Aleutians West	2	Ketchikan Gateway	8	Southeast Fairbanks	3
Anchorage	56	Kodiak Island	6	Valdez-Cordova	2
Bethel	4	Lake and Peninsula	0	Wade Hampton	2
Bristol Bay	0	Matanuska-Susitna	18	Wrangell-Petersburg	0
Denali	0	Nome	5	Yakutat	0
Dillingham	3	North Slope	2	Yukon-Koyukuk	6
Fairbanks North Star	22	Northwest Arctic	3	Unknown	0
Haines	0	Prince of Wales-Outer Ketchikan	3		
Juneau	4	Sitka	8		

Stage at Diagnosis



Hodgkin's Disease

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using all primary sites with morphology codes 9650 - 9667. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 201.0 -201.9.


1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
In situ cancer*	n/a	n/a	n/a
Invasive cancer	13	14	27
Incidence rate	4.4	4.3	4.3
1995 U.S. rate	3.0	2.3	2.6
*In situ cancers are not applicable (n/a)			
<u>Mortality</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
Deaths	0	1	1
Mortality rate	0	n/c**	n/c**
1995 U.S. rate	0.6	0.4	0.5
** n/c = rate not calculated if $n<5$			

Hodgkin's Disease by Borough/Census Area

0	•	0			
Aleutians East	0	Kenai Peninsula	2	Skagway-Hoonah-Angoon	0
Aleutians West	0	Ketchikan Gateway	0	Southeast Fairbanks	0
Anchorage	12	Kodiak Island	1	Valdez-Cordova	0
Bethel	0	Lake and Peninsula	0	Wade Hampton	0
Bristol Bay	0	Matanuska-Susitna	5	Wrangell-Petersburg	0
Denali	0	Nome	0	Yakutat	0
Dillingham	0	North Slope	0	Yukon-Koyukuk	1
Fairbanks North Star	5	Northwest Arctic	0	Unknown	0
Haines	0	Prince of Wales-Outer Ketchikan	0		
Juneau	1	Sitka	0		





Kidney and Renal Pelvis

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C64.9 and C65.9, and excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 189.0 and 189.1.


1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
In situ cancer	0	0	0
Invasive cancer	27	12	39
Incidence rate	13.6	6.3	10.1
1995 U.S. rate*	12.8	6.3	9.2
*Excludes in situ cases			
<u>Mortality</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
Deaths	10	9	19
Mortality rate	5.8	5.4	5.7
1995 U.Š. rate	5.0	2.4	3.6

Kidney and Renal Pelvis Cancer by Borough/Census Area

Aleutians East	0	Kenai Peninsula	2	Skagway-Hoonah-Angoon	0
Aleutians West	1	Ketchikan Gateway	2	Southeast Fairbanks	1
Anchorage	16	Kodiak Island	0	Valdez-Cordova	0
Bethel	0	Lake and Peninsula	0	Wade Hampton	1
Bristol Bay	0	Matanuska-Susitna	5	Wrangell-Petersburg	0
Denali	1	Nome	1	Yakutat	1
Dillingham	0	North Slope	0	Yukon-Koyukuk	1
Fairbanks North Star	4	Northwest Arctic	1	Unknown	0
Haines	0	Prince of Wales-Outer Ketchikan	0		
Juneau	1	Sitka	1		

Stage at Diagnosis



Leukemias

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 code C42.1 with morphology codes 9800 - 9941. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 204.0 - 208.9.

<u>Incidence</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
n situ cancer*	n/a	n/a	n/a
Invasive cancer	29	19	48
Incidence rate	13.9	9.5	11.6
1995 U.S. rate	12.9	7.9	10.1
In situ cancers are not applicable (n/a)			
Mortality	Male	<u>Female</u>	<u>Total</u>
Deaths	16	10	26
Mortality rate	8.1	5.2	6.6
1995 U.Š. rate	8.4	4.8	6.3

1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

Leukemias by Borough/Census Area

J	0				
Aleutians East	0	Kenai Peninsula	8	Skagway-Hoonah-Angoon	2
Aleutians West	0	Ketchikan Gateway	1	Southeast Fairbanks	0
Anchorage	16	Kodiak Island	1	Valdez-Cordova	0
Bethel	0	Lake and Peninsula	1	Wade Hampton	0
Bristol Bay	0	Matanuska-Susitna	9	Wrangell-Petersburg	1
Denali	0	Nome	1	Yakutat	0
Dillingham	0	North Slope	0	Yukon-Koyukuk	0
Fairbanks North Star	1	Northwest Arctic	0	Unknown	0
Haines	0	Prince of Wales-Outer Ketchikan	1		
Juneau	5	Sitka	1		

Stage at Diagnosis**

**All leukemias are staged as distant/systemic disease

5 year Survival (U.S., 1995)

All leukemias 42.8%

Lung and Bronchus


Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C34.0 - C34.9, excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 162.2 - 162.9.

1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
In situ cancer	1	0	1
Invasive cancer	144	106	250
Incidence rate*	77.0	57.9	67.0
1995 U.S. rate*	73.4	42.6	55.9
*Excludes in situ cases			
Mortality	<u>Male</u>	<u>Female</u>	<u>Total</u>
Deaths	110	74	184
Mortality rate	66.4	42.1	53.4
1995 U.S. rate	69.5	34.2	49.3

Invasive Lung Cancer by Borough/Census Area

	J				
Aleutians East	1	Kenai Peninsula	34	Skagway-Hoonah-Angoon	2
Aleutians West	4	Ketchikan Gateway	4	Southeast Fairbanks	1
Anchorage	102	Kodiak Island	7	Valdez-Cordova	5
Bethel	0	Lake and Peninsula	1	Wade Hampton	4
Bristol Bay	0	Matanuska-Susitna	19	Wrangell-Petersburg	5
Denali	0	Nome	5	Yakutat	1
Dillingham	6	North Slope	1	Yukon-Koyukuk	2
Fairbanks North Star	23	Northwest Arctic	3	Unknown	0
Haines	1	Prince of Wales-Outer Ketchikan	3		
Juneau	13	Sitka	3		



Melanomas of the Skin

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C44.0-C44.9, including only morphology codes 8720-8790. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 172.2 - 172.9.


s per 100,000 population age-adjusted to 1970 U.S. population				
Incidence	Male	Female	Total	
In situ cancer	${2}$	9	11	
Invasive cancer	24	22	46	
Incidence rate*	10.9	7.8	9.3	
1995 U.S. rate*	16.2	11.1	13.3	
*Excludes in situ cases				
<u>Mortality</u>	Male	<u>Female</u>	<u>Total</u>	
Deaths	11	3	14	
Mortality rate	4.9	n/c**	3.0	
1995 U.Š. rate	3.2	1.5	2.2	
**n/c = rate not calculated if n<5				

1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

Invasive Melanomas of the Skin by Borough/Census Area

		v b			
Aleutians East	0	Kenai Peninsula	4	Skagway-Hoonah-Angoon	0
Aleutians West	0	Ketchikan Gateway	1	Southeast Fairbanks	2
Anchorage	19	Kodiak Island	1	Valdez-Cordova	0
Bethel	0	Lake and Peninsula	0	Wade Hampton	0
Bristol Bay	0	Matanuska-Susitna	5	Wrangell-Petersburg	1
Denali	0	Nome	0	Yakutat	0
Dillingham	0	North Slope	1	Yukon-Koyukuk	0
Fairbanks North Star	3	Northwest Arctic	0	Unknown	3
Haines	0	Prince of Wales-Outer Ketchikan	0		
Juneau	3	Sitka	3		





Non-Hodgkin's Lymphomas

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using all primary sites with morphology codes 9590 - 9595 and 9670 - 9714. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 200.0 - 200.8, 202.0 - 202.2 and 202.8 - 202.9.


er 100,000 population age-adjusted to 1970 U.S. population				
Incidence	<u>Male</u>	<u>Female</u>	<u>Total</u>	
In situ cancer*	n/a	n/a	n/a	
Invasive cancer	32	27	59	
Incidence rate	13.6	13.0	13.7	
1995 U.S. rate	20.3	12.3	16.0	
*In situ cancers are not applicable (n/a)				
<u>Mortality</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>	
Deaths	16	12	28	
Mortality rate	7.0	6.8	7.1	
1995 U.S. rate	8.5	5.6	6.9	

1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

Non-Hodgkin's Lymphomas by Borough/Census Area

Aleutians East	1	Kenai Peninsula	4	Skagway-Hoonah-Angoon	0
Aleutians West	0	Ketchikan Gateway	1	Southeast Fairbanks	1
Anchorage	31	Kodiak Island	0	Valdez-Cordova	3
Bethel	1	Lake and Peninsula	0	Wade Hampton	0
Bristol Bay	0	Matanuska-Susitna	5	Wrangell-Petersburg	1
Denali	0	Nome	0	Yakutat	0
Dillingham	0	North Slope	0	Yukon-Koyukuk	0
Fairbanks North Star	7	Northwest Arctic	1	Unknown	0
Haines	1	Prince of Wales-Outer Ketchikan	0		
Juneau	0	Sitka	2		

Stage at Diagnosis



Oral Cavity and Pharynx

1996 Alaska Residents


Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C00.0 - C14.8, and excluding morphology codes 9590 - 9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 140.0 - 149.9

Incidence and Mortality Summary by Sex	
rates per 100,000 population age-adjusted to 1970 U.S. population	

<u>Incidence</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
In situ cancer	3	2	5
Invasive cancer	27	16	43
Incidence rate*	13.2	8.6	11.2
1995 U.S. rate*	14.7	6.0	10.0
*Excludes in situ cases			
<u>Mortality</u>	Male	<u>Female</u>	<u>Total</u>
Deaths	9	2	11
Mortality rate	5.0	n/c**	2.8
1995 U.S. rate	4.1	1.5	2.7
** n/c = rate not calculated if $n<5$			

Invasive Cancer of the Oral Cavity and Pharynx by Borough/Census Area

			0		
Aleutians East	0	Kenai Peninsula	2	Skagway-Hoonah-Angoon	1
Aleutians West	1	Ketchikan Gateway	1	Southeast Fairbanks	1
Anchorage	16	Kodiak Island	1	Valdez-Cordova	0
Bethel	0	Lake and Peninsula	0	Wade Hampton	0
Bristol Bay	0	Matanuska-Susitna	3	Wrangell-Petersburg	2
Denali	1	Nome	0	Yakutat	1
Dillingham	0	North Slope	0	Yukon-Koyukuk	1
Fairbanks North Star	8	Northwest Arctic	0	Unknown	0
Haines	0	Prince of Wales-Outer Ketchikan	0		
Juneau	2	Sitka	2		



Ovary

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 code C56.9, excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 code 183.0


s per 100,000 population age-adjusted to 1970 U.S. population				
Incidence	<u>Female</u>			
In situ cancer	0			
Invasive cancer	36			
Incidence rate	14.2			
1995 U.S. rate*	14.4			
*Excludes in situ cases				
<u>Mortality</u>	<u>Female</u>			
Deaths	13			
Mortality rate	6.9			
1995 U.Š. rate	7.6			

1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

Ovarian Cancer by Borough/Census Area

o fui fuir cuircer	<i>wj wvi</i>				
Aleutians East	0	Kenai Peninsula	6	Skagway-Hoonah-Angoon	0
Aleutians West	0	Ketchikan Gateway	1	Southeast Fairbanks	1
Anchorage	19	Kodiak Island	2	Valdez-Cordova	0
Bethel	3	Lake and Peninsula	0	Wade Hampton	1
Bristol Bay	0	Matanuska-Susitna	0	Wrangell-Petersburg	0
Denali	0	Nome	0	Yakutat	0
Dillingham	0	North Slope	0	Yukon-Koyukuk	0
Fairbanks North Star	3	Northwest Arctic	0	Unknown	0
Haines	0	Prince of Wales-Outer Ketchikan	0		
Juneau	0	Sitka	0		

Stage at Diagnosis



Pancreas

Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C25.0-C25.9, excluding morphology codes 9590 - 9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 157.0 - 157.9.


1996 Alaska Residents
Incidence and Mortality Summary by Sex
rates per 100,000 population age-adjusted to 1970 U.S. population

Incidence	<u>Male</u>	<u>Female</u>	<u>Total</u>
In situ cancer	0	0	0
Invasive cancer	19	18	37
Incidence rate	11.1	9.3	10.1
1995 U.S. rate*	9.7	7.6	8.5
*Excludes in situ cases			
<u>Mortality</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
Deaths	16	19	35
Mortality rate	10.0	9.8	9.7
1995 U.S. rate	9.6	7.2	8.3

Pancreatic Cancer by Borough/Census Area

0	Kenai Peninsula	3	Skagway-Hoonah-Angoon	0
2	Ketchikan Gateway	1	Southeast Fairbanks	0
14	Kodiak Island	0	Valdez-Cordova	0
0	Lake and Peninsula	0	Wade Hampton	1
0	Matanuska-Susitna	5	Wrangell-Petersburg	0
0	Nome	0	Yakutat	0
1	North Slope	1	Yukon-Koyukuk	0
5	Northwest Arctic	1	Unknown	0
1	Prince of Wales-Outer Ketchikan	0		
2	Sitka	0		
	2 14 0 0 0 1 5 1	 2 Ketchikan Gateway 14 Kodiak Island 0 Lake and Peninsula 0 Matanuska-Susitna 0 Nome 1 North Slope 5 Northwest Arctic 1 Prince of Wales-Outer Ketchikan 	2Ketchikan Gateway114Kodiak Island00Lake and Peninsula00Matanuska-Susitna50Nome01North Slope15Northwest Arctic11Prince of Wales-Outer Ketchikan0	2Ketchikan Gateway1Southeast Fairbanks14Kodiak Island0Valdez-Cordova0Lake and Peninsula0Wade Hampton0Matanuska-Susitna5Wrangell-Petersburg0Nome0Yakutat1North Slope1Yukon-Koyukuk5Northwest Arctic1Unknown1Prince of Wales-Outer Ketchikan0

Stage at Diagnosis



Prostate


Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 code C61.9, excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 code 185.

e-adjusted to 1970 U.S. population	
<u>Male</u>	
0	
193	
111.2	
137.2	
Male	
18	
13.3	
24.9	
	<u>Male</u> 0 193 111.2 137.2 <u>Male</u> 18 13.3

1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

Prostate Cancer by Borough/Census Area

Aleutians East	Ŭ O	Kenai Peninsula	21	Skagway-Hoonah-Angoon	2
Aleutians West	1	Ketchikan Gateway	6	Southeast Fairbanks	2
Anchorage	73	Kodiak Island	8	Valdez-Cordova	8
Bethel	0	Lake and Peninsula	0	Wade Hampton	0
Bristol Bay	0	Matanuska-Susitna	13	Wrangell-Petersburg	4
Denali	0	Nome	3	Yakutat	0
Dillingham	2	North Slope	1	Yukon-Koyukuk	3
Fairbanks North Star	24	Northwest Arctic	0	Unknown	0
Haines	1	Prince of Wales-Outer Ketchikan	2		
Juneau	15	Sitka	4		



Stomach

- - -


Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C16.0 - C16.9, excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 151.0 - 151.9.

1996 Alaska Residents
Incidence and Mortality Summary by Sex
rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
In situ cancer	0	0	0
Invasive cancer	21	10	31
Incidence rate	10.9	5.3	8.1
1995 U.S. rate*	9.8	4.1	6.6
*Excludes in situ cases			
<u>Mortality</u>	<u>Male</u>	<u>Female</u>	<u>Total</u>
Deaths	23	6	29
Mortality rate	12.9	2.6	7.7
1995 U.S. rate	6.0	2.8	4.2

Stomach Cancer by Borough/Census Area

Aleutians East	1	Kenai Peninsula	0	Skagway-Hoonah-Angoon	0
Aleutians West	0	Ketchikan Gateway	0	Southeast Fairbanks	0
Anchorage	15	Kodiak Island	1	Valdez-Cordova	2
Bethel	0	Lake and Peninsula	0	Wade Hampton	1
Bristol Bay	1	Matanuska-Susitna	0	Wrangell-Petersburg	2
Denali	0	Nome	0	Yakutat	0
Dillingham	1	North Slope	2	Yukon-Koyukuk	0
Fairbanks North Star	3	Northwest Arctic	0	Unknown	0
Haines	1	Prince of Wales-Outer Ketchikan	1		
Juneau	0	Sitka	0		



Thyroid


Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 code C73.9, excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 code 193.

<u>Incidence</u>	<u>Male</u>	Female	<u>Total</u>
In situ cancer	0	0	0
Invasive cancer	3	40	43
Incidence rate	n/c**	15.1	8.1
1995 U.S. rate*	2.9	7.8	5.4
*Excludes in situ cases			
**n/c=rate not calculated if n<5			
<u>Mortality</u>	Male	<u>Female</u>	<u>Total</u>
Deaths	0	0	0
Mortality rate	0	0	0
1995 U.S. rate	0.3	0.3	0.3

1996 Alaska Residents Incidence and Mortality Summary by Sex 100 000 1.4 1070 TI 0 ... rat

Thyroid Cancer by Borough/Census Area

Aleutians East	0	Kenai Peninsula	2	Skagway-Hoonah-Angoon	1
Aleutians West	0	Ketchikan Gateway	1	Southeast Fairbanks	1
Anchorage	18	Kodiak Island	3	Valdez-Cordova	0
Bethel	0	Lake and Peninsula	0	Wade Hampton	1
Bristol Bay	1	Matanuska-Susitna	1	Wrangell-Petersburg	0
Denali	1	Nome	0	Yakutat	0
Dillingham	0	North Slope	1	Yukon-Koyukuk	0
Fairbanks North Star	6	Northwest Arctic	1	Unknown	0
Haines	0	Prince of Wales-Outer Ketchikan	0		
Juneau	5	Sitka	0		



Uterus


Data Definition: Incidence data were obtained from the Alaska Cancer Registry using primary site ICD-O-2 codes C54.0 - C54.9 and C55.9, and excluding morphology codes 9590-9989. Mortality data were obtained from Alaska State death certificates using the underlying cause of death ICD-9 codes 179, 182.0 - 182.1 and 182.8.

1996 Alaska Residents Incidence and Mortality Summary by Sex rates per 100,000 population age-adjusted to 1970 U.S. population

<u>Incidence</u>	<u>Female</u>
In situ cancer	0
Invasive cancer	35
Incidence rate	16.8
1995 U.S. rate*	21.9
*Excludes in situ cases	
<u>Mortality</u>	<u>Female</u>
Deaths	3
Mortality rate	n/c**
1995 U.S. rate	3.3
**n/c=rate not calculated if n<5	

Uterine Cancer by Borough/Census Area

	J	0				
Aleutians East		0	Kenai Peninsula	4	Skagway-Hoonah-Angoon	1
Aleutians West		0	Ketchikan Gateway	1	Southeast Fairbanks	1
Anchorage		15	Kodiak Island	0	Valdez-Cordova	1
Bethel		0	Lake and Peninsula	0	Wade Hampton	0
Bristol Bay		0	Matanuska-Susitna	3	Wrangell-Petersburg	0
Denali		0	Nome	0	Yakutat	0
Dillingham		0	North Slope	0	Yukon-Koyukuk	0
Fairbanks North Star		3	Northwest Arctic	0	Unknown	0
Haines		2	Prince of Wales-Outer Ketchikan	0		
Juneau		4	Sitka	0		



Section III

	All Ages	00)-04	0	5-09	1()-14	15	-19	2	0-24	2	5-29	3	30-34	3	5-39		40-44
Site of Cancer	#	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
All Sites	1600	12	0.8%	2	0.1%	5	0.3%	4	0.3%	17	1.1%	27	1.7%	37	2.3%	53	3.3%	126	7.9%
Oral Cavity & Pharynx	43	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	2.3%	0	0.0%	0	0.0%	3	7.0%
Lip	3	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	33.3%	0	0.0%	0	0.0%	0	0.0%
Tongue	9	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Salivary Glands	4	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Floor of Mouth	3	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Gum & Other Mouth	9	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Nasopharynx	2	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Tonsil	7	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	28.6%
Oropharynx	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	100.0%
Hypopharynx	4	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Oral Cavity	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Digestive System	280	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.7%	5	1.8%	7	2.5%	19	6.8%
Esophagus	14	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	7.1%
Stomach	31	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.2%	1	3.2%	1	3.2%	1	3.2%
Small Intestine	5	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	20.0%	1	20.0%
Colon & Rectum	166	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	1.8%	4	2.4%	11	6.6%
Colon	113	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	2.7%	2	1.8%	5	4.4%
Rectum & Rectosigmoid	53	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	3.8%	6	11.3%
Anus, Anal Canal & Anorectum	3	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Liver & Intrahepatic Bile Ducts	17	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	5.9%	0	0.0%	0	0.0%	1	5.9%

	All Ages	45	-49	50)-54	55	-59	60	-64	6	5-69	7)-74	7	5-79	8	0-84	8	85+
Site of Cancer	#	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
All Sites	1600	136	8.5%	158	9.9%	185	11.6%	183	11.4%	218	13.6%	196	12.3%	111	6.9%	80	5.0%	50	3.1%
Oral Cavity & Pharynx	43	0	0.0%	9	20.9%	2	4.7%	7	16.3%	10	23.3%	5	11.6%	3	7.0%	2	4.7%	1	2.3%
Lip	3	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	33.3%	1	33.3%	0	0.0%	0	0.0%	0	0.0%
Tongue	9	0	0.0%	2	22.2%	0	0.0%	2	22.2%	3	33.3%	1	11.1%	1	11.1%	0	0.0%	0	0.0%
Salivary Glands	4	0	0.0%	1	25.0%	0	0.0%	0	0.0%	2	50.0%	0	0.0%	1	25.0%	0	0.0%	0	0.0%
Floor of Mouth	3	0	0.0%	1	33.3%	0	0.0%	1	33.3%	0	0.0%	1	33.3%	0	0.0%	0	0.0%	0	0.0%
Gum & Other Mouth	9	0	0.0%	1	11.1%	2	22.2%	1	11.1%	1	11.1%	1	11.1%	1	11.1%	1	11.1%	1	11.1%
Nasopharynx	2	0	0.0%	1	50.0%	0	0.0%	0	0.0%	1	50.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Tonsil	7	0	0.0%	2	28.6%	0	0.0%	1	14.3%	1	14.3%	0	0.0%	0	0.0%	1	14.3%	0	0.0%
Oropharynx	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Hypopharynx	4	0	0.0%	0	0.0%	0	0.0%	2	50.0%	1	25.0%	1	25.0%	0	0.0%	0	0.0%	0	0.0%
Other Oral Cavity	1	0	0.0%	1	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Digestive System	280	18	6.4%	24	8.6%	26	9.3%	37	13.2%	45	16.1%	37	13.2%	20	7.1%	20	7.1%	20	7.1%
Esophagus	14	2	14.3%	1	7.1%	1	7.1%	1	7.1%	2	14.3%	3	21.4%	1	7.1%	0	0.0%	2	14.3%
Stomach	31	1	3.2%	2	6.5%	4	12.9%	8	25.8%	2	6.5%	5	16.1%	2	6.5%	2	6.5%	1	3.2%
Small Intestine	5	1	20.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	20.0%	0	0.0%	0	0.0%	1	20.0%
Colon & Rectum	166	11	6.6%	16	9.6%	14	8.4%	20	12.1%	29	17.5%	19	11.5%	16	9.6%	13	7.8%	10	6.0%
Colon	113	5	4.4%	12	10.6%	9	8.0%	13	11.5%	20	17.7%	12	10.6%	15	13.3%	8	7.1%	9	8.0%
Rectum & Rectosigmoid	53	6	11.3%	4	7.6%	5	9.4%	7	13.2%	9	17.0%	7	13.2%	1	1.9%	5	9.4%	1	1.9%
Anus, Anal Canal & Anorectum	3	1	33.3%	1	33.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	33.3%
Liver & Intrahepatic Bile Ducts	17	0	0.0%	0	0.0%	3	17.7%	3	17.7%	2	11.8%	4	23.5%	1	5.9%	2	11.8%	0	0.0%

	All Ages	00	-04	0	5-09	1()-14	15	-19	2	20-24	2	5-29	3	30-34	3	5-39		40-44
Site of Cancer	#	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Liver	14	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	7.1%	0	0.0%	0	0.0%	1	7.1%
Intrahepatic Bile Duct	3	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Gallbladder	2	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Biliary Tract	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	100.0%	0	0.0%	0	0.0%
Pancreas	37	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	2.7%	3	8.1%
Retroperitoneum	2	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	50.0%
Peritoneum, Omentum & Mesentery	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Digestive Organs	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Respiratory System	282	0	0.0%	0	0.0%	0	0.0%	1	0.4%	0	0.0%	0	0.0%	0	0.0%	3	1.1%	8	2.8%
Nasal Cavity, Middle Ear & Accessory	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Larynx	20	0	0.0%	0	0.0%	0	0.0%	1	5.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Lung & Bronchus	250	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	1.2%	8	3.2%
Pleura	9	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Trachea & Other	2	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bones & Joints	6	0	0.0%	0	0.0%	1	16.7%	0	0.0%	2	33.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Soft Tissue (Incl Heart)	15	2	13.3%	0	0.0%	0	0.0%	0	0.0%	1	6.7%	0	0.0%	1	6.7%	0	0.0%	4	26.7%
Skin (excl basal & squamous)	47	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	2.1%	0	0.0%	6	12.8%	8	17.0%
Melanoma of the Skin	46	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	2.2%	0	0.0%	6	13.0%	7	15.2%
Other Skin	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	100.0%
Breast	262	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.4%	8	3.1%	12	4.6%	31	11.8%
Female Genital System	99	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	2.0%	4	4.0%	4	4.0%	7	7.1%	17	17.2%

	All Ages	43	5-49	5	0-54	55	5-59	60	-64	6	65-69	7	0-74		75-79	8	80-84		85+
Site of Cancer	#	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Liver	14	0	0.0%	0	0.0%	0	0.0%	3	17.7%	2	14.3%	4	28.6%	1	7.1%	2	14.3%	0	0.0%
Intrahepatic Bile Duct	3	0	0.0%	0	0.0%	3	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Gallbladder	2	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	100.0%	0	0.0%	0	0.0%	0	0.0%
Other Biliary Tract	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Pancreas	37	1	2.7%	3	8.1%	4	10.8%	5	13.5%	10	27.0%	3	8.1%	0	0.0%	2	5.4%	5	13.5%
Retroperitoneum	2	0	0.0%	1	50.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Peritoneum, Omentum & Mesentery	1	1	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Digestive Organs	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	100.0%	0	0.0%
Respiratory System	282	19	6.7%	25	8.9%	35	12.4%	51	18.1%	53	18.8%	44	15.6%	20	7.1%	14	5.0%	9	3.2%
Nasal Cavity, Middle Ear & Accessory	1	0	0.0%	0	0.0%	0	0.0%	1	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Larynx	20	2	10.0%	2	10.0%	3	15.0%	4	20.0%	3	15.0%	3	15.0%	1	5.0%	1	5.0%	0	0.0%
Lung & Bronchus	250	17	6.8%	23	9.2%	31	12.4%	44	17.6%	48	19.2%	37	14.8%	18	7.2%	12	4.8%	9	3.6%
Pleura	9	0	0.0%	0	0.0%	0	0.0%	2	22.2%	2	22.2%	3	33.3%	1	11.1%	1	11.1%	0	0.0%
Trachea & Other	2	0	0.0%	0	0.0%	1	50.0%	0	0.0%	0	0.0%	1	50.0%	0	0.0%	0	0.0%	0	0.0%
Bones & Joints	6	0	0.0%	1	16.7%	1	16.7%	1	16.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Soft Tissue (Incl Heart)	15	1	6.7%	2	13.3%	1	6.7%	1	6.7%	1	6.7%	0	0.0%	1	6.7%	0	0.0%	0	0.0%
Skin (excl basal & squamous)	47	2	4.3%	10	21.3%	6	12.8%	2	4.3%	3	6.4%	3	6.4%	4	8.5%	2	4.3%	0	0.0%
Melanoma of the Skin	46	2	4.4%	10	21.7%	6	13.0%	2	4.4%	3	6.5%	3	6.5%	4	8.7%	2	4.4%	0	0.0%
Other Skin	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Breast	262	46	17.6%	42	16.0%	31	11.8%	28	10.7%	13	5.0%	20	7.6%	18	6.9%	7	2.7%	5	1.9%
Female Genital System	99	11	11.1%	6	6.1%	13	13.1%	10	10.1%	9	9.1%	10	10.1%	1	1.0%	3	3.0%	2	2.0%

1996 Cancer in Alaska

	All Ages	0	0-04	0	5-09	1	0-14	15	-19		20-24	2	5-29	:	30-34	3	85-39		40-44
Site of Cancer	#	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Cervix Uteri	26	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	7.7%	3	11.5%	2	7.7%	3	11.5%	4	15.4%
Corpus Uteri	31	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.2%	0	0.0%	4	12.9%
Uterus NOS	4	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	50.0%
Ovary	36	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	2.8%	1	2.8%	4	11.1%	7	19.4%
Vagina	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Vulva	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Female Genital Organs	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Male Genital System	211	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.5%	2	1.0%	5	2.4%	4	1.9%	6	2.8%
Prostate	193	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	1.6%
Testis	18	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	5.6%	2	11.1%	5	27.8%	4	22.2%	3	16.7%
Penis	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Male Genital Organs	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Urinary System	105	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	1.0%	2	1.9%	1	1.0%	2	1.9%	3	2.9%
Urinary Bladder (including in situ)	60	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	3.3%	1	1.7%	1	1.7%	1	1.7%
Kidney and Renal Pelvis	39	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	2.6%	0	0.0%	0	0.0%	1	2.6%	2	5.1%
Ureter	4	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Urinary Organs	2	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Eye & Orbit	3	2	66.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Brain & Nervous System	27	1	3.7%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	2	7.4%	1	3.7%	3	11.1%	4	14.8%
Brain	26	1	3.9%	1	3.9%	0	0.0%	0	0.0%	0	0.0%	2	7.7%	1	3.9%	3	11.5%	3	11.5%
Cranial Nerves & Other	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	100.0%

	All Ages	45	5-49	5	0-54	55	5-59	60	-64	6	5-69	7	0-74		75-79	8	80-84		85+
Site of Cancer	#	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Cervix Uteri	26	4	15.4%	2	7.7%	3	11.5%	1	3.9%	1	3.9%	1	3.9%	0	0.0%	0	0.0%	0	0.0%
Corpus Uteri	31	2	6.5%	2	6.5%	6	19.4%	6	19.4%	5	16.1%	2	6.5%	0	0.0%	3	9.7%	0	0.0%
Uterus NOS	4	0	0.0%	0	0.0%	0	0.0%	1	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	25.0%
Ovary	36	5	13.9%	2	5.6%	3	8.3%	2	5.6%	3	8.3%	6	16.7%	1	2.8%	0	0.0%	1	2.8%
Vagina	1	0	0.0%	0	0.0%	1	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Vulva	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	100.0%	0	0.0%	0	0.0%	0	0.0%
Other Female Genital Organs	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Male Genital System	211	13	6.2%	12	5.7%	30	14.2%	23	10.9%	40	19.0%	42	19.9%	18	8.5%	9	4.3%	6	2.8%
Prostate	193	10	5.2%	12	6.2%	30	15.5%	23	11.9%	40	20.7%	42	21.8%	18	9.3%	9	4.7%	6	3.1%
Testis	18	3	16.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Penis	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Male Genital Organs	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Urinary System	105	3	3.8%	9	8.6%	21	20.0%	8	7.6%	19	18.1%	15	14.3%	11	10.5%	6	5.7%	3	2.9%
Urinary Bladder (including in situ)	60	3	5.0%	5	8.3%	10	16.7%	6	10.0%	12	20.0%	6	10.0%	7	11.7%	4	6.7%	2	3.3%
Kidney and Renal Pelvis	39	0	0.0%	4	10.3%	11	28.2%	2	5.1%	6	15.4%	7	18.0%	2	5.1%	2	5.1%	1	2.6%
Ureter	4	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	25.0%	2	50.0%	1	25.0%	0	0.0%	0	0.0%
Other Urinary Organs	2	1	50.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	50.0%	0	0.0%	0	0.0%
Eye & Orbit	3	0	0.0%	1	33.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Brain & Nervous System	27	3	11.1%	2	7.4%	5	18.5%	2	7.4%	2	7.4%	1	3.7%	0	0.0%	0	0.0%	0	0.0%
Brain	26	3	11.5%	2	7.7%	5	19.2%	2	7.7%	2	7.7%	1	3.9%	0	0.0%	0	0.0%	0	0.0%
Cranial Nerves & Other	1	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

	All Ages	0	0-04	0	5-09	1	0-14	15	5-19	2	20-24	2	5-29	:	30-34	3	35-39		40-44
Site of Cancer	#	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Endocrine System	45	1	2.2%	0	0.0%	1	2.2%	0	0.0%	6	13.3%	4	8.9%	2	4.4%	4	8.9%	6	13.3%
Thyroid	43	0	0.0%	0	0.0%	0	0.0%	0	0.0%	6	14.0%	4	9.3%	2	4.7%	4	9.3%	6	14.0%
Thymus & Other	2	1	50.0%	0	0.0%	1	50.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Lymphomas	86	0	0.0%	0	0.0%	1	1.2%	3	3.5%	4	4.7%	6	7.0%	9	10.5%	4	4.7%	8	9.3%
Hodgkin's Disease	27	0	0.0%	0	0.0%	1	3.7%	2	7.4%	2	7.4%	5	18.5%	8	29.6%	0	0.0%	3	11.1%
Non-Hodgkin's Lymphomas	59	0	0.0%	0	0.0%	0	0.0%	1	1.7%	2	3.4%	1	1.7%	1	1.7%	4	6.8%	5	8.5%
Multiple Myeloma	17	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	11.8%
Leukemias	48	6	12.5%	1	2.1%	2	4.2%	0	0.0%	0	0.0%	2	4.2%	1	2.1%	1	2.1%	4	8.3%
Lymphocytic	17	4	23.5%	1	5.9%	1	5.9%	0	0.0%	0	0.0%	1	5.9%	1	5.9%	0	0.0%	1	5.9%
Myeloid	22	1	4.6%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	4.6%	0	0.0%	1	4.6%	1	4.6%
Monocytic	2	0	0.0%	0	0.0%	1	50.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Leukemia	7	1	14.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	28.6%
Ill Defined & Unspecified Sites	24	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	12.5%

	All Ages	00)-04	0	5-09	1()-14	15	-19	2	0-24	2	5-29	3	80-34	3	5-39	4	40-44
Site of Cancer	#	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Endocrine System	45	6	13.3%	3	6.7%	3	6.7%	2	4.4%	2	4.4%	2	4.4%	1	2.2%	1	2.2%	1	2.2%
Thyroid	43	6	14.0%	3	7.0%	3	7.0%	2	4.7%	2	4.7%	2	4.7%	1	2.3%	1	2.3%	1	2.3%
Thymus & Other	2	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Lymphomas	86	8	9.3%	7	8.1%	7	8.1%	2	2.3%	12	14.0%	5	5.8%	4	4.7%	5	5.8%	1	1.2%
Hodgkin's Disease	27	2	7.4%	0	0.0%	2	7.4%	0	0.0%	1	3.7%	1	3.7%	0	0.0%	0	0.0%	0	0.0%
Non-Hodgkin's Lymphomas	59	6	10.2%	7	11.9%	5	8.5%	2	3.4%	11	18.6%	4	6.8%	4	6.8%	5	8.5%	1	1.7%
Multiple Myeloma	17	1	5.9%	1	5.9%	1	5.9%	1	5.9%	3	17.7%	3	17.7%	4	23.5%	1	5.9%	0	0.0%
Leukemias	48	2	4.2%	2	4.2%	3	6.3%	4	8.3%	5	10.4%	5	10.4%	3	6.3%	7	14.6%	0	0.0%
Lymphocytic	17	1	5.9%	2	11.8%	1	5.9%	0	0.0%	1	5.9%	1	5.9%	2	11.8%	0	0.0%	0	0.0%
Myeloid	22	1	4.6%	0	0.0%	2	9.1%	3	13.6%	3	13.6%	3	13.6%	0	0.0%	6	27.3%	0	0.0%
Monocytic	2	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	50.0%	0	0.0%	0	0.0%
Other Leukemia	7	0	0.0%	0	0.0%	0	0.0%	1	14.3%	1	14.3%	1	14.3%	0	0.0%	1	14.3%	0	0.0%
Ill Defined & Unspecified Sites	24	2	8.3%	2	8.3%	0	0.0%	4	16.7%	1	4.2%	4	16.7%	3	12.5%	3	12.5%	2	8.3%

		INCIDEN	CE				MORTA	LITY		
	# of	Rate per	95%	5 CI	91-95	# of	Rate per	95%	% CI	91-95
Site of Cancer	<u>Cases</u>	<u>100,000</u>			<u>US Rate</u>		<u>100,000</u>			<u>US Rate</u>
All Sites	1600	386.8	366.8	407.8	410.1	648	177.6	160.3	Ī88.9	171.4
Oral Cavity & Pharynx	43	11.2	8.0	15.4	10.5	11	2.8	1.3	5.3	2.8
Lip	3	n/c	n/c	n/c	1.1	0	0.0	n/c	n/c	0.0
Tongue	9	2.5	1.1	5.0	2.2	3	n/c	n/c	n/c	0.6
Salivary Glands	4	n/c	n/c	n/c	1.0	2	n/c	n/c	n/c	0.2
Floor of Mouth	3	n/c	n/c	n/c	1.0	0	0.0	n/c	n/c	0.1
Gum & Other Mouth	9	2.7	1.2	5.3	1.9	2	n/c	n/c	n/c	0.5
Nasopharynx	2	n/c	n/c	n/c	0.6	2	n/c	n/c	n/c	0.2
Tonsil	7	1.5	0.5	3.7	1.1	0	0.0	n/c	n/c	0.2
Oropharynx	1	n/c	n/c	n/c	0.3	0	0.0	n/c	n/c	0.2
Hypopharynx	4	n/c	n/c	n/c	1.0	1	n/c	n/c	n/c	0.2
Other Oral Cavity	1	n/c	n/c	n/c	0.4	1	n/c	n/c	n/c	0.6
Digestive System	280	73.8	64.9	83.7	74.3	150	42.6	35.3	49.8	39.4
Esophagus	14	3.7	1.9	6.6	3.9	11	3.2	1.6	6.1	3.6
Stomach	31	8.1	5.4	11.9	7.2	29	7.7	5.0	11.4	4.4
Small Intestine	5	1.0	0.3	3.0	1.3	2	n/c	n/c	n/c	0.3
Colon & Rectum	166	43.9	37.1	51.7	45.2	62	18.8	14.2	24.2	17.8
Colon	113	31.0	25.3	37.8	32.7	52	15.7	11.5	20.7	n/c
Rectum & Rectosigmoid	53	12.9	9.4	17.4	12.6	10	3.1	1.5	5.8	n/c
Anus, Anal Canal & Anorectum	3	n/c	n/c	n/c	1.0	1	n/c	n/c	n/c	0.1
Liver & Intrahepatic Bile Ducts	17	4.8	2.7	7.9	3.6	9	2.3	1.0	4.6	3.3
Liver	14	4.1	2.2	7.1	3.0	8	2.0	0.8	4.3	2.7
Intrahepatic Bile Duct	3	n/c	n/c	n/c	0.6	1	n/c	n/c	n/c	0.6
Gallbladder	2	n/c	n/c	n/c	1.0	1	n/c	n/c	n/c	0.7
Other Biliary Tract	1	n/c	n/c	n/c	1.1	0	0.0	n/c	n/c	0.5
Pancreas	37	10.1	6.9	14.3	8.9	35	9.7	6.6	13.9	8.4
Retroperitoneum	2	n/c	n/c	n/c	0.4	0	0.0	n/c	n/c	0.1
Peritoneum, Omentum & Mesentery	1	n/c	n/c	n/c	0.4	0	0.0	n/c	n/c	0.1
Other Digestive Organs	1	n/c	n/c	n/c	0.3	0	0.0	n/c	n/c	0.1

Table 2-a. Total Cancer Incidence and Mortality by Site - Alaska, 1996

Note: Rate is not calculated (n/c) where number is less than 5

1996 Cancer in Alas

Table 2-a. Total Cancer Incidence and Mortality by Site - Alaska, 1996

		INCIDEN	CE				MORTA	LITY		
	# of	Rate per	95%	5 CI	91-95	# of	Rate per	9 59	% CI	91-95
Site of Cancer	<u>Cases</u>	<u>100,000</u>	Lower	<u>Upper</u>	<u>US Rate</u>	<u>Cases</u>	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>
Respiratory System	282	75.8	66.9	85.7	63.8	185	53.6	46.0	62.3	51.6
Nasal Cavity, Middle Ear & Accessory	1	n/c	n/c	n/c	0.6	0	0.0	n/c	n/c	0.2
Larynx	20	5.2	3.1	8.3	4.1	0	0.0	n/c	n/c	1.4
Lung & Bronchus	250	67.0	58.6	76.3	58.1	184	53.4	45.8	62.1	49.8
Pleura	9	2.8	1.3	5.5	0.8	0	0.0	n/c	n/c	0.1
Trachea & Other	2	n/c	n/c	n/c	0.2	1	n/c	n/c	n/c	0.1
Bones & Joints	6	1.4	0.5	3.4	0.9	1	n/c	n/c	n/c	0.4
Soft Tissue (Incl Heart)	15	2.7	1.4	5.0	2.3	9	1.8	0.8	3.9	1.2
Skin (excl basal & squamous)	47	9.4	6.6	13.1	16.5	16	3.5	1.9	6.2	2.9
Melanoma of the Skin	46	9.3	6.5	13.0	12.7	14	3.0	1.6	5.6	2.2
Other Skin	1	n/c	n/c	n/c	3.9	2	n/c	n/c	n/c	0.7
Breast (female and male)	262	54.1	47.1	61.9	60.5	53	12.2	8.9	16.5	14.5
Female Genital System	99	20.2	16.0	25.2	25.6	25	6.5	4.1	10.0	8.2
Cervix Uteri	26	4.2	2.7	6.8	4.2	6	1.2	0.4	3.1	1.5
Corpus Uteri	31	7.5	4.9	11.0	11.6	1	n/c	n/c	n/c	1.0
Uterus NOS	4	n/c	n/c	n/c	0.2	2	n/c	n/c	n/c	0.9
Ovary	36	7.0	4.7	10.3	8.0	13	3.5	1.8	6.4	4.3
Vagina	1	n/c	n/c	n/c	0.3	1	n/c	n/c	n/c	0.1
Vulva	1	n/c	n/c	n/c	0.9	1	n/c	n/c	n/c	0.2
Other Female Genital Organs	0	0.0	n/c	n/c	0.4	1	n/c	n/c	n/c	0.1
Male Genital System	211	56.1	48.5	64.7	72.7	20	6.4	3.8	10.1	10.1
Prostate	193	54.0	46.4	62.6	70.0	18	6.0	3.5	9.6	10.0
Testis	18	2.1	1.2	4.0	2.3	1	n/c	n/c	n/c	0.1
Penis	0	0.0	n/c	n/c	0.3	0	0.0	n/c	n/c	0.1
Other Male Genital Organs	0	0.0	n/c	n/c	0.1	1	n/c	n/c	n/c	0.0
Urinary System	105	27.9	22.6	34.2	26.9	32	10.1	6.8	14.3	6.9
Urinary Bladder (including in situ)	60	16.0	12.1	21.0	17.0	12	4.0	2.0	7.1	3.2
Kidney & Renal Pelvis	39	10.1	7.1	14.2	9.3	19	5.7	3.4	9.1	3.5
Ureter	4	n/c	n/c	n/c	0.4	1	n/c	n/c	n/c	0.1
Other Urinary Organs	2	n/c	n/c	n/c	0.3	0	0.0	n/c	n/c	0.1

Note: Rate is not calculated (n/c) where number is less than 5

Table 2-a. Total Cancer Incidence and Mortality by Site - Alaska, 1996

		INCIDEN	CE				MORTA	LITY		
	# of	Rate per	95%	5 CI	91-95	# of	Rate per	9 5%	% CI	91-95
Site of Cancer	<u>Cases</u>	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	US Rate	Cases	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>
Eye & Orbit	3	n/c	n/c	n/c	0.7	0	0.0	n/c	n/c	0.1
Brain & Other Nervous System	27	4.7	2.9	7.5	6.1	23	4.2	2.5	6.9	4.2
Brain	26	4.6	2.9	7.3	5.7	22	4.1	2.4	6.8	4.1
Cranial Nerves & Other	1	n/c	n/c	n/c	0.4	1	n/c	n/c	n/c	0.1
Endocrine System	45	8.5	6.0	11.9	5.6	1	n/c	n/c	n/c	0.7
Thyroid	43	8.1	5.7	11.6	5.1	0	0.0	n/c	n/c	0.3
Thymus & Other	2	n/c	n/c	n/c	0.6	1	n/c	n/c	n/c	0.3
Lymphomas	86	18.0	14.1	22.9	18.5	29	7.4	4.8	11.0	7.2
Hodgkin's Disease	27	4.3	2.8	6.9	2.7	1	n/c	n/c	n/c	0.5
Non-Hodgkin's Lymphomas	59	13.7	10.2	18.2	15.8	28	7.1	4.6	10.7	6.7
Multiple Myeloma	17	4.6	2.6	7.7	4.5	12	4.0	2.0	7.0	3.1
Leukemias	48	11.6	8.4	15.9	10.3	26	6.6	4.1	10.2	6.3
Lymphocytic	17	3.4	1.9	5.9	4.6	9	2.7	1.2	5.5	1.9
Myeloid	22	6.1	3.7	9.6	4.3	13	2.8	1.3	5.3	2.7
Monocytic	2	n/c	n/c	n/c	0.2	1	n/c	n/c	n/c	0.1
Other Leukemia	7	1.6	0.6	3.9	1.2	3	n/c	n/c	n/c	1.7
Ill Defined & Unspecified Sites	24	6.6	4.1	10.2	10.1	55	15.6	11.6	20.7	11.8

Table 2-b. Male Cancer Incidence and Mortality by Site - Alaska, 1996

	INCIDENCE					MORTALITY				
	# of	Rate per	95%	5 CI	91-95	# of	Rate per	95%	% CI	91-95
Site of Cancer	<u>Cases</u>	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>	<u>Cases</u>	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>
All Sites	782	406.1	375.7	438.8	500.5	354	204.7	182.3	$2\bar{2}9.7$	215.7
Oral Cavity & Pharynx	27	13.2	8.5	20.6	15.8	9	5.0	2.1	10.7	4.3
Lip	1	n/c	n/c	n/c	2.1	0	0.0	n/c	n/c	0.1
Tongue	5	2.6	0.8	7.6	3.2	2	n/c	n/c	n/c	0.9
Salivary Glands	1	n/c	n/c	n/c	1.3	2	n/c	n/c	n/c	0.3
Floor of Mouth	3	n/c	n/c	n/c	1.5	0	0.0	n/c	n/c	0.1
Gum & Other Mouth	2	n/c	n/c	n/c	2.5	2	n/c	n/c	n/c	0.6
Nasopharynx	2	n/c	n/c	n/c	0.9	2	n/c	n/c	n/c	0.4
Tonsil	6	2.8	0.8	8.0	1.7	0	0.0	n/c	n/c	0.3
Oropharynx	0	0.0	n/c	n/c	0.5	0	0.0	n/c	n/c	0.3
Hypopharynx	3	n/c	n/c	n/c	1.7	1	n/c	n/c	n/c	0.3
Other Oral Cavity	1	n/c	n/c	n/c	0.6	0	0.0	n/c	n/c	0.9
Digestive System	153	82.2	68.4	98.6	92.8	90	53.6	42.4	67.6	51.0
Esophagus	8	4.0	1.4	9.8	6.4	8	4.6	1.8	10.7	6.2
Stomach	21	10.9	6.5	18.1	10.7	23	12.9	7.9	20.8	6.3
Small Intestine	4	n/c	n/c	n/c	1.7	2	n/c	n/c	n/c	0.4
Colon & Rectum	88	48.1	37.6	61.3	54.5	34	21.5	14.4	31.4	21.9
Colon	59	33.3	24.6	44.8	38.0	28	17.6	11.3	26.9	n/c
Rectum & Rectosigmoid	29	14.8	9.3	23.1	16.4	6	3.8	1.4	9.4	n/c
Anus, Anal Canal & Anorectum	1	n/c	n/c	n/c	0.8	1	n/c	n/c	n/c	0.1
Liver & Intrahepatic Bile Ducts	9	5.5	2.5	11.6	5.5	5	2.5	0.8	7.5	4.7
Liver	8	5.1	2.2	11.1	4.7	5	2.5	0.8	7.5	4.0
Intrahepatic Bile Duct	1	n/c	n/c	n/c	0.8	0	0.0	n/c	n/c	0.7
Gallbladder	1	n/c	n/c	n/c	0.7	1	n/c	n/c	n/c	0.4
Other Biliary Tract	0	0.0	n/c	n/c	1.3	0	0.0	n/c	n/c	0.6
Pancreas	19	11.1	6.3	18.8	10.3	16	10.0	5.4	17.6	9.9
Retroperitoneum	1	n/c	n/c	n/c	0.4	0	0.0	n/c	n/c	0.1
Peritoneum, Omentum & Mesentery	1	n/c	n/c	n/c	0.2	0	0.0	n/c	n/c	0.1
Other Digestive Organs	0	0.0	n/c	n/c	0.3	0	0.0	n/c	n/c	0.2

Note: Rate is not calculated (n/c) where number is less than 5

	INCIDENCE					MORTALITY				
	# of	Rate per	95%	5 CI	91-95	# of	Rate per	95%	% CI	91-95
Site of Cancer	<u>Cases</u>	<u>100,000</u>	Lower	<u>Upper</u>	<u>US Rate</u>	Cases	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>
Respiratory System	171	92.5	78.3	109.2	88.3	111	66.8	54.4	81.8	75.1
Nasal Cavity, Middle Ear & Accessory	1	n/c	n/c	n/c	0.8	0	0.0	n/c	n/c	0.2
Larynx	15	8.0	4.3	14.5	7.3	0	0.0	n/c	n/c	2.5
Lung & Bronchus	144	77.0	64.1	92.5	78.3	110	66.4	54.0	81.4	72.0
Pleura	9	5.9	2.7	12.3	1.6	0	0.0	n/c	n/c	0.3
Trachea & Other	2	n/c	n/c	n/c	0.3	1	n/c	n/c	n/c	0.2
Bones & Joints	2	n/c	n/c	n/c	1.1	1	n/c	n/c	n/c	0.5
Soft Tissue (Incl Heart)	7	2.8	1.0	7.7	2.7	4	n/c	n/c	n/c	1.3
Skin (excl basal & squamous)	25	11.1	6.8	18.2	22.3	13	5.8	2.8	11.8	4.3
Melanoma of the Skin	24	10.9	6.7	18.0	15.5	11	4.9	2.2	10.7	3.1
Other Skin	1	n/c	n/c	n/c	6.8	2	n/c	n/c	n/c	1.2
Breast (male)	1	n/c	n/c	n/c	0.9	0	0.0	n/c	n/c	0.3
Female Genital System	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cervix Uteri	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Corpus Uteri	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Uterus NOS	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Ovary	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Vagina	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Vulva	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Female Genital Organs	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Male Genital System	211	115.2	99.1	133.7	168.2	20	14.2	8.4	23.0	26.5
Prostate	193	111.2	95.3	129.6	162.7	18	13.3	7.7	22.0	26.1
Testis	18	4.0	2.3	8.5	4.5	1	n/c	n/c	n/c	0.2
Penis	0	0.0	n/c	n/c	0.7	0	0.0	n/c	n/c	0.2
Other Male Genital Organs	0	0.0	n/c	n/c	0.3	1	n/c	n/c	n/c	0.0
Urinary System	73	40.2	31.0	52.0	43.3	22	14.5	8.9	23.1	10.8
Urinary Bladder (including in situ)	41	23.6	16.5	33.5	29.3	11	8.0	3.9	15.2	5.6
Kidney & Renal Pelvis	27	13.6	8.8	21.2	12.8	10	5.8	2.7	11.9	5.0
Ureter	3	n/c	n/c	n/c	0.7	1	n/c	n/c	n/c	0.1
Other Urinary Organs	2	n/c	n/c	n/c	0.4	0	0.0	n/c	n/c	0.1

Table 2-b. Male Cancer Incidence and Mortality by Site - Alaska, 1996

Note: Rate is not calculated (n/c) where number is less than 5

Table 2-b. Male Cancer Incidence and Mortality by Site - Alaska, 1996

	INCIDENCE					MORTALITY				
	# of	Rate per	95%	CI	91-95	# of	Rate per	95 %	% CI	91-95
Site of Cancer	<u>Cases</u>	<u>100,000</u>	Lower	<u>Upper</u>	<u>US Rate</u>	Cases	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>
Eye & Orbit	2	n/c	n/c	n/c	0.9	0	0.0	n/c	n/c	0.1
Brain & Other Nervous System	18	6.2	3.5	11.7	7.3	17	5.8	3.1	11.3	5.1
Brain	17	6.0	3.3	11.5	6.9	16	5.5	2.9	10.9	5.0
Cranial Nerves & Other	1	n/c	n/c	n/c	0.4	1	n/c	n/c	n/c	0.1
Endocrine System	4	n/c	n/c	n/c	3.5	1	n/c	n/c	n/c	0.7
Thyroid	3	n/c	n/c	n/c	2.9	0	0.0	n/c	n/c	0.3
Thymus & Other	1	n/c	n/c	n/c	0.6	1	n/c	n/c	n/c	0.4
Lymphomas	45	18.0	12.7	25.8	22.7	16	7.0	3.7	13.2	8.9
Hodgkin's Disease	13	4.4	2.2	9.4	3.0	0	0.0	n/c	n/c	0.6
Non-Hodgkin's Lymphomas	32	13.6	9.0	21.0	19.7	16	7.0	3.7	13.2	8.2
Multiple Myeloma	6	3.3	1.1	8.9	5.6	7	5.6	2.2	12.5	3.8
Leukemias	29	13.9	8.8	21.7	13.2	16	8.1	4.2	15.0	8.4
Lymphocytic	12	4.7	2.3	10.1	6.0	6	3.8	1.1	9.8	2.6
Myeloid	11	6.3	2.9	12.8	5.2	7	2.5	0.9	7.2	3.4
Monocytic	0	0.0	n/c	n/c	0.3	1	n/c	n/c	n/c	0.1
Other Leukemia	6	2.8	0.9	8.1	1.7	2	n/c	n/c	n/c	2.3
Ill Defined & Unspecified Sites	8	3.2	1.2	8.5	11.8	27	15.9	10.2	24.4	14.6

Table 2-c. Female Cancer Incidence and Mortality by Site - Alaska, 1996

	INCIDENCE					MORTALITY					
	# of	Rate per	95%	CI	91-95	# of	Rate per	95%	6 CI	91-95	
Site of Cancer	<u>Cases</u>	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>	Cases	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>	
All Sites	818	375.6	348.8	404.2	347.5	294	155.1	137.2	174.8	141.5	
Oral Cavity & Pharynx	16	8.6	4.8	14.3	6.0	2	n/c	n/c	n/c	1.6	
Lip	1	n/c	n/c	n/c	0.3	0	0.0	n/c	n/c	0.0	
Tongue	4	n/c	n/c	n/c	1.4	1	n/c	n/c	n/c	0.4	
Salivary Glands	3	n/c	n/c	n/c	0.8	0	0.0	n/c	n/c	0.1	
Floor of Mouth	0	0.0	n/c	n/c	0.5	0	0.0	n/c	n/c	0.1	
Gum & Other Mouth	5	3.0	0.9	7.2	1.3	0	0.0	n/c	n/c	0.3	
Nasopharynx	0	0.0	n/c	n/c	0.4	0	0.0	n/c	n/c	0.1	
Tonsil	1	n/c	n/c	n/c	0.6	0	0.0	n/c	n/c	0.1	
Oropharynx	1	n/c	n/c	n/c	0.1	0	0.0	n/c	n/c	0.1	
Hypopharynx	1	n/c	n/c	n/c	0.4	0	0.0	n/c	n/c	0.1	
Other Oral Cavity	0	0.0	n/c	n/c	0.2	1	n/c	n/c	n/c	0.3	
Digestive System	127	66.6	55.1	79.9	60.0	60	32.6	24.6	42.3	30.7	
Esophagus	6	3.6	1.3	7.9	1.8	3	n/c	n/c	n/c	1.5	
Stomach	10	5.3	2.5	10.1	4.6	6	2.6	0.9	6.4	2.9	
Small Intestine	1	n/c	n/c	n/c	1.1	0	0.0	n/c	n/c	0.3	
Colon & Rectum	78	41.1	32.2	51.9	38.2	28	16.5	10.9	24.0	14.9	
Colon	54	29.4	21.9	38.8	28.7	24	14.1	9.0	21.1	n/c	
Rectum & Rectosigmoid	24	11.8	7.3	18.0	9.5	4	n/c	n/c	n/c	n/c	
Anus, Anal Canal & Anorectum	2	n/c	n/c	n/c	1.0	0	0.0	n/c	n/c	0.1	
Liver & Intrahepatic Bile Ducts	8	4.0	1.7	8.4	2.1	4	n/c	n/c	n/c	2.1	
Liver	6	3.1	1.0	7.1	1.6	3	n/c	n/c	n/c	1.6	
Intrahepatic Bile Duct	2	n/c	n/c	n/c	0.5	1	n/c	n/c	n/c	0.5	
Gallbladder	1	n/c	n/c	n/c	1.3	0	0.0	n/c	n/c	0.8	
Other Biliary Tract	1	n/c	n/c	n/c	1.0	0	0.0	n/c	n/c	0.5	
Pancreas	18	9.3	5.3	15.1	7.8	19	9.8	5.8	15.6	7.3	
Retroperitoneum	1	n/c	n/c	n/c	0.4	0	0.0	n/c	n/c	0.1	
Peritoneum, Omentum & Mesentery	0	0.0	n/c	n/c	0.5	0	0.0	n/c	n/c	0.1	
Other Digestive Organs	1	n/c	n/c	n/c	0.2	0	0.0	n/c	n/c	0.1	

Note: Rate is not calculated (n/c) where number is less than 5

Table 2-c. Female Cancer Incidence and Mortality by Site - Alaska, 1996

		INCIDEN	CE				MORTA	LITY		
	# of	Rate per	95%	CI	91-95	# of	Rate per	95 9	% CI	91-95
Site of Cancer	<u>Cases</u>	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>	<u>Cases</u>	<u>100,000</u>			<u>US Rate</u>
Respiratory System	111	60.3	49.4	73.0	45.3	74	42.1	32.9	$\bar{53.1}$	34.1
Nasal Cavity, Middle Ear & Accessory	0	0.0	n/c	n/c	0.5	0	0.0	n/c	n/c	0.1
Larynx	5	2.4	0.7	6.1	1.5	0	0.0	n/c	n/c	0.5
Lung & Bronchus	106	57.9	47.2	70.4	43.0	74	42.1	32.9	53.1	33.3
Pleura	0	0.0	n/c	n/c	0.3	0	0.0	n/c	n/c	0.1
Trachea & Other	0	0.0	n/c	n/c	0.1	0	0.0	n/c	n/c	0.1
Bones & Joints	4	n/c	n/c	n/c	0.8	0	0.0	n/c	n/c	0.3
Soft Tissue (Incl Heart)	8	2.8	1.1	6.3	2.0	5	1.9	0.6	5.2	1.2
Skin (excl basal & squamous)	22	7.8	4.6	12.7	11.7	3	n/c	n/c	n/c	1.8
Melanoma of the Skin	22	7.8	4.6	12.7	10.6	3	n/c	n/c	n/c	1.5
Other Skin	0	0.0	n/c	n/c	1.1	0	0.0	n/c	n/c	0.3
Breast (female)	261	109.3	95.5	124.7	110.9	53	24.1	17.7	32.4	26
Female Genital System	99	41.0	32.7	51.0	47.4	25	12.8	8.1	19.3	14.6
Cervix Uteri	26	8.9	5.6	14.0	8.0	6	2.6	0.9	6.2	2.8
Corpus Uteri	31	15.1	10.1	22.1	21.2	1	n/c	n/c	n/c	1.7
Uterus NOS	4	n/c	n/c	n/c	0.3	2	n/c	n/c	n/c	1.6
Ovary	36	14.2	9.6	20.5	14.8	13	6.9	3.5	12.1	7.7
Vagina	1	n/c	n/c	n/c	0.6	1	n/c	n/c	n/c	0.2
Vulva	1	n/c	n/c	n/c	1.7	1	n/c	n/c	n/c	0.3
Other Female Genital Organs	0	0.0	n/c	n/c	0.7	1	n/c	n/c	n/c	0.2
Male Genital System	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Prostate	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Testis	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Penis	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Male Genital Organs	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Urinary System	32	16.4	11.0	23.6	14.5	10	6.1	2.9	11.3	4.2
Urinary Bladder (including in situ)	19	9.5	5.6	15.2	7.7	1	n/c	n/c	n/c	1.7
Kidney & Renal Pelvis	12	6.3	3.2	11.4	6.4	9	5.4	2.5	10.3	2.3
Ureter	1	n/c	n/c	n/c	0.3	0	0.0	n/c	n/c	0.1
Other Urinary Organs	0	0.0	n/c	n/c	0.2	0	0.0	n/c	n/c	0.1

Note: Rate is not calculated (n/c) where number is less than 5

Table 2-c. Female Cancer Incidence and Mortality by Site - Alaska, 1996

	INCIDENCE					MORTALITY					
	# of	Rate per	95%		91-95	# of	Rate per	95 %	% CI	91-95	
Site of Cancer	<u>Cases</u>	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>	Cases	<u>100,000</u>	<u>Lower</u>	<u>Upper</u>	<u>US Rate</u>	
Eye & Orbit	1	n/c	n/c	n/c	0.6	0	0.0	n/c	n/c	0.1	
Brain & Other Nervous System	9	3.3	1.4	7.0	5.0	6	2.4	0.8	6.1	3.5	
Brain	9	3.3	1.4	7.0	4.7	6	2.4	0.8	6.1	3.4	
Cranial Nerves & Other	0	0.0	n/c	n/c	0.3	0	0.0	n/c	n/c	0.1	
Endocrine System	41	15.4	10.8	21.8	7.7	0	0.0	n/c	n/c	0.6	
Thyroid	40	15.0	10.5	21.4	7.2	0	0.0	n/c	n/c	0.4	
Thymus & Other	1	n/c	n/c	n/c	0.5	0	0.0	n/c	n/c	0.3	
Lymphomas	41	17.3	11.9	24.3	14.9	13	7.4	3.9	12.9	5.8	
Hodgkin's Disease	14	4.3	2.2	8.0	2.5	1	n/c	n/c	n/c	0.4	
Non-Hodgkin's Lymphomas	27	13.0	8.3	19.6	12.4	12	6.8	3.5	12.1	5.4	
Multiple Myeloma	11	6.0	2.9	11.0	3.7	5	3.1	1.0	7.3	2.6	
Leukemias	19	9.5	5.6	15.4	8.0	10	5.2	2.3	10.0	4.9	
Lymphocytic	5	1.9	0.6	5.2	3.4	3	n/c	n/c	n/c	1.3	
Myeloid	11	6.0	2.9	11.1	3.6	6	2.7	0.9	6.6	2.2	
Monocytic	2	n/c	n/c	n/c	0.2	0	0.0	n/c	n/c	0.1	
Other Leukemia	1	n/c	n/c	n/c	0.8	1	n/c	n/c	n/c	1.3	
Ill Defined & Unspecified Sites	16	9.3	5.3	15.4	8.9	28	15.3	10.1	22.5	9.6	

Note: Rate is not calculated (n/c) where number is less than 5

Page 59

Appendices

APPENDIX I

International Classification of Diseases for Onocology - 2nd Edition (ICD-O-2) and International Classification of Diseases - 9th Revision (ICD-9) Codes Used for Grouping Sites of Cancer

ipC00.0 - C00.9 $140.0 - 140.9$ ongueC01.9 - C02.9 $141.0 - 141.9$ alivary glandsC07.9 - C08.9 $142.0 - 142.9$ loor of mouthC04.0 - C04.9 $144.0 - 144.9$ um and other mouthC03.0 - C03.9, C05.0 - C05.9, C06.0 - C06.9 $143.0 - 143.9, 145.0 - 145.6, 145.8 - 145.5$ asopharynxC11.0 - C11.9 $147.0 - 147.9$ onsilC09.0 - C09.9 $146.0 - 146.2$ ropharynxC10.0 - C10.9 $146.3 - 146.9$ ypopharynxC12.9, C13.0 - C13.9, C14.1 $148.0 - 148.9$ ther oral cavity and pharynxC14.0, C14.2 - C14.8 $149.0 - 149.9$ gestive systemsepsitive $50.0 - 150.9$ gorkie systemC15.0 - C15.9 $150.0 - 150.9$ tomachC16.0 - C16.9 $151.0 - 151.9$ mall intestineC17.0 - C17.9 $152.0 - 152.9$ olorectalC19.9, C20.9 $154.0 - 154.1$ rus, anal canal and anorectumC21.0 - C21.2, C21.8 $154.2 - 154.3, 154.8$ alloladderC23.9 156.0 ther and interpatic bile ductC22.0, C22.1 $156.1 - 156.9$ alloladderC23.9 156.0 ther billaryC44.0 - C24.9 $156.1 - 156.9$ ancreasC25.0 - C25.9 $157.0 + 157.9$ etropertioneumC48.0 158.0 etropertioneumC48.0 158.0	SITE OF CANCER	ICD-0-2* codes	ICD-9 codes
İngue C01.9 - C02.9 141.0 - 141.9 alivary glands C07.9 - C08.9 142.0 - 142.9 loor of mouth C04.0 - C04.9 144.0 - 144.9 um and other mouth C03.0 - C03.9, C05.0 - C05.9, C06.0 - C06.9 143.0 - 143.9, 145.6, 145.8 - 145.5 asopharynx C11.0 - C11.9 147.0 - 147.9 onsil C09.0 - C09.9 146.0 - 146.2 ropharynx C10.0 - C10.9 146.3 - 146.9 ypopharynx C12.9, C13.0 - C13.9, C14.1 148.0 - 148.9 ther oral cavity and pharynx C15.0 - C15.9 150.0 - 150.9 gestive system sopharynx C16.0 - C16.9 151.0 - 151.9 mall intestine C17.0 - C17.9 152.0 - 152.9 150.0 - 150.9 olorectal C11.0 - C11.2, C21.8 154.0 - 154.1 148.0 us, and canal and anorectum C16.0 - C16.9 151.0 - 151.9 152.0 - 152.9 olorectal C10.0 - C18.9, C26.0 153.0 - 153.9, 159.0 154.0 - 154.1 us, and canal and anorectum C21.0 - C21.2, C21.8 154.2 - 154.3, 154.8 154.0 - 154.1 iver an intrahepatic bile duct C22	Oral cavity and pharynx		
alivary glandsC07.9 - C08.9142.0 - 142.9loor of mouthC04.0 - C04.9144.0 - 144.9um and other mouthC03.0 - C03.9, C05.0 - C05.9, C06.0 - C06.9143.0 - 143.9, 145.0 - 145.6, 145.8 - 145.5asopharynxC11.0 - C11.9147.0 - 147.9onsilC09.0 - C09.9146.0 - 146.2ropharynxC10.0 - C10.9146.0 - 148.9ther or al cavity and pharynxC12.9, C13.0 - C13.9, C14.1148.0 - 148.9gestive systemc14.0, C14.2 - C14.8149.0 - 149.9gestive systemc16.0 - C16.9150.0 - 150.9gestive systemc16.0 - C16.9150.0 - 150.9alivary glandsC17.0 - C17.9150.0 - 150.9olorectalc17.0 - C17.9152.0 - 152.9olorectalc17.0 - C18.9, C26.0153.0 - 153.9, 159.0Rectum and rectosignoidC19.9, C20.9154.0 - 154.1nus, anal canal and anorectumC21.0 - C21.2, C21.8154.2 - 154.3, 154.8ver and intrahepatic bile ductC22.0, C22.1155.0, 155.1, 155.2alibladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperinonumC48.0158.0etroperinonumC48.0158.0	Lip	C00.0 - C00.9	140.0 - 140.9
for of mouth C04.0 - C04.9 144.0 - 144.9 um and other mouth C03.0 - C03.9, C05.0 - C05.9, C06.0 - C06.9 143.0 - 143.9, 145.0 - 145.6, 145.8 - 145.8 asopharynx C11.0 - C11.9 147.0 - 147.9 onsil C09.0 - C09.9 146.0 - 146.2 typpharynx C10.0 - C10.9 146.3 - 146.9 typpoharynx C12.9, C13.0 - C13.9, C14.1 148.0 - 148.9 ther oral cavity and pharynx C14.0, C14.2 - C14.8 149.0 - 149.9 gestive system sophagus C15.0 - C15.9 150.0 - 150.9 sophagus C15.0 - C15.9 150.0 - 150.9 150.0 - 151.9 mall intestine C17.0 - C17.9 152.0 - 152.9 150.0 - 150.9 olorectal C19.0, C20.9 153.0 - 153.9, 159.0 150.0 - 154.1 us, and canal and anorectum C21.0 - C21.2, C21.8 154.2 - 154.3, 154.8 149.0 - 148.9 vier and intrahepatic bile duct C22.0, C22.1 155.0, 155.1, 155.2 131.0 - 151.9 allbladder C23.9 156.0 154.0 - 154.9 156.0 vier and intrahepatic bile duct C22.0, C22.1 156.0 156	Tongue	C01.9 - C02.9	141.0 - 141.9
um and other mouth C03.0 - C03.9, C05.0 - C05.9, C06.0 - C06.9 143.0 - 143.9, 145.0 - 145.6, 145.8 - 145.9, asopharynx C11.0 - C11.9 147.0 - 147.9 onsil C09.0 - C09.9 146.0 - 146.2 ropharynx C10.0 - C10.9 146.3 - 146.9 ypopharynx C12.9, C13.0 - C13.9, C14.1 148.0 - 148.9 ypopharynx C14.0, C14.2 - C14.8 149.0 - 149.9 gestive system 500.0 - 150.9 150.0 - 150.9 gestive system 500.0 - C15.9 150.0 - 150.9 sophagus C16.0 - C16.9 151.0 - 151.9 nand intestine C17.0 - C17.9 152.0 - 152.9 olorectal Colon excluding rectum C18.0 - C18.9, C26.0 153.0 - 153.9, 159.0 Recturn and rectosigmoid C19.9, C20.9 154.0 - 154.1 nus, anal canal and anorectum C21.0 - C21.2, C21.8 154.2 - 154.3, 154.8 vier and intrahepatic bile duct C22.0, C22.1 155.0, 155.1, 155.2 allbladder C23.9 156.0 ther biliary C24.0 - C24.9 156.1 - 156.9 ancreas C25.0 - C25.0 157.0 - 157.9	Salivary glands	C07.9 - C08.9	142.0 - 142.9
asopharynx C11.0 - C11.9 147.0 - 147.9 onsil C09.0 - C09.9 146.0 - 146.2 ropharynx C10.0 - C10.9 146.3 - 146.9 ypopharynx C12.9, C13.0 - C13.9, C14.1 148.0 - 148.9 ther or al cavity and pharynx C14.0, C14.2 - C14.8 149.0 - 149.9 gestive system 500 150.0 - 150.9 150.0 - 150.9 gestive system 151.0 - C15.9 150.0 - 150.9 150.0 - 151.9 sophagus C17.0 - C17.9 152.0 - 152.9 150.0 - 153.9, 159.0 olorectal C19.0, C20.9 154.0 - 154.1 149.0 - 144.1 nus, anal canal and anorectum C21.0 - C21.2, C21.8 154.0 - 154.1 nus, anal canal and anorectum C22.0, C22.1 155.0, 155.1, 155.2 allbladder C23.9 156.0 ther biliary C24.0 - C24.9 156.1 - 156.9 ancreas C25.0 - C25.9 157.0 - 157.9 etroperitoneum C48.0 158.0 eritoneum, omentum and mesentery C48.1 - C48.2 158.8 - 158.9	Floor of mouth	C04.0 - C04.9	144.0 - 144.9
Onsil C09.0 - C09.9 146.0 - 146.2 iropharynx C10.0 - C10.9 146.3 - 146.9 iyoppharynx C12.9, C13.0 - C13.9, C14.1 148.0 - 148.9 ither oral cavity and pharynx C14.0, C14.2 - C14.8 149.0 - 149.9 gestive system 150.0 - 150.9 150.0 - 150.9 sophagus C15.0 - C15.9 150.0 - 150.9 tomach C16.0 - C16.9 151.0 - 151.9 mall intestine C17.0 - C17.9 152.0 - 152.9 olorectal 150.0 - C15.9, C20.9 154.0 - 154.1 colon excluding rectum C18.0 - C18.9, C26.0 153.0 - 153.9, 159.0 Rectum and rectosignoid C19.9, C20.9 154.0 - 154.1 nus, and canal and anorectum C21.0 - C21.2, C21.8 154.2 - 154.3, 154.8 iver and intrahepatic bile duct C22.0, C22.1 155.0, 155.1, 155.2 allbladder C23.9 156.0 ther biliary C41.0 - C24.9 156.1 - 156.9 ancreas C25.0 - C25.9 157.0 - 157.9 etroperitoneum C48.0 158.0 eritoneum, omentum and mesentery C48.1 - C	Gum and other mouth	C03.0 - C03.9, C05.0 - C05.9, C06.0 - C06.9	143.0 - 143.9, 145.0 - 145.6, 145.8 - 145.9
ropharynx C10.0 - C10.9 146.3 - 146.9 ypopharynx C12.9, C13.0 - C13.9, C14.1 148.0 - 148.9 ther oral cavity and pharynx C14.0, C14.2 - C14.8 149.0 - 149.9 gestive system sophagus C15.0 - C15.9 150.0 - 150.9 tomach C16.0 - C16.9 151.0 - 151.9 anal intestine C17.0 - C17.9 152.0 - 152.9 olorectal Colon excluding rectum C18.0 - C18.9, C26.0 153.0 - 153.9, 159.0 Rectum and rectosigmoid C19.9, C20.9 154.0 - 154.1 nus, anal canal and anorectum C21.0 - C21.2, C21.8 154.2 - 154.3, 154.8 iver and intrahepatic bile duct C22.0, C22.1 155.0, 155.1, 155.2 allbladder C23.9 156.0 ther biliary C24.0 - C24.9 156.1 - 156.9 ancreas C25.0 - C25.9 157.0 - 157.9 etroperitoneum C48.0 158.0 etroperitoneum and mesentery C48.1 - C48.2 158.8 - 158.9	Nasopharynx	C11.0 - C11.9	147.0 - 147.9
Sypopharynx C12.9, C13.0 - C13.9, C14.1 148.0 - 148.9 ther oral cavity and pharynx C14.0, C14.2 - C14.8 149.0 - 149.9 gestive system 500 150.0 - 150.9 sophagus C15.0 - C15.9 150.0 - 150.9 tomach C16.0 - C16.9 151.0 - 151.9 mall intestine C17.0 - C17.9 152.0 - 152.9 olorectal C10 - C18.9, C26.0 153.0 - 153.9, 159.0 Rectum and rectosigmoid C19.9, C20.9 154.0 - 154.1 nus, anal canal and anorectum C21.0 - C21.2, C21.8 154.2 - 154.3, 154.8 wer and intrahepatic bile duct C22.0, C22.1 155.0, 155.2 allbladder C23.9 156.0 ther biliary C24.0 - C24.9 156.1 - 156.9 ancreas C25.0 - C25.9 157.0 - 157.9 etroperitoneum C48.0 158.0 eritoneum, omentum and mesentery C48.1 - C48.2 158.8 - 158.9	Tonsil	C09.0 - C09.9	146.0 - 146.2
ther or al cavity and pharynx C14.0, C14.2 - C14.8 149.0 - 149.9 gestive system sophagus C15.0 - C15.9 150.0 - 150.9 sophagus C16.0 - C16.9 151.0 - 151.9 tomach C16.0 - C17.9 152.0 - 152.9 olorectal C19.9, C20.9 153.0 - 153.9, 159.0 Rectum and rectosigmoid C19.9, C20.9 154.0 - 154.1 nus, anal canal and anorectum C21.0 - C21.2, C21.8 155.0, 155.1, 155.2 idlbladder C23.9 156.0 ther biliary C24.0 - C24.9 156.1 - 156.9 ancreas C25.0 - C25.9 157.0 - 157.9 etroperitoneum C48.0 158.0	Oropharynx	C10.0 - C10.9	146.3 - 146.9
gestive system sophagus C15.0 - C15.9 150.0 - 150.9 tomach C16.0 - C16.9 151.0 - 151.9 mall intestine C17.0 - C17.9 152.0 - 152.9 olorectal	Hypopharynx	C12.9, C13.0 - C13.9, C14.1	148.0 - 148.9
SophagusC15.0 - C15.9150.0 - 150.9tomachC16.0 - C16.9151.0 - 151.9mall intestineC17.0 - C17.9152.0 - 152.9olorectalColon excluding rectumC18.0 - C18.9, C26.0153.0 - 153.9, 159.0Rectum and rectosigmoidC19.9, C20.9154.0 - 154.1nus, anal canal and anorectumC21.0 - C21.2, C21.8154.2 - 154.3, 154.8iver and intrahepatic bile ductC22.0, C22.1155.0, 155.1, 155.2allbladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Other oral cavity and pharynx	C14.0, C14.2 - C14.8	149.0 - 149.9
TomachC16.0 - C16.9151.0 - 151.9mall intestineC17.0 - C17.9152.0 - 152.9olorectalColon excluding rectumC18.0 - C18.9, C26.0153.0 - 153.9, 159.0Rectum and rectosigmoidC19.9, C20.9154.0 - 154.1nus, anal canal and anorectumC21.0 - C21.2, C21.8154.2 - 154.3, 154.8iver and intrahepatic bile ductC22.0, C22.1155.0, 155.1, 155.2allbladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Digestive system		
mall intestine olorectalC17.0 - C17.9152.0 - 152.9Colon excluding rectumC18.0 - C18.9, C26.0153.0 - 153.9, 159.0Rectum and rectosigmoidC19.9, C20.9154.0 - 154.1nus, anal canal and anorectumC21.0 - C21.2, C21.8154.2 - 154.3, 154.8iver and intrahepatic bile ductC22.0, C22.1155.0, 155.1, 155.2allbladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Esophagus	C15.0 - C15.9	150.0 - 150.9
olorectalC18.0 - C18.9, C26.0153.0 - 153.9, 159.0Rectum and rectosigmoidC19.9, C20.9154.0 - 154.1nus, anal canal and anorectumC21.0 - C21.2, C21.8154.2 - 154.3, 154.8iver and intrahepatic bile ductC22.0, C22.1155.0, 155.1, 155.2allbladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Stomach	C16.0 - C16.9	151.0 - 151.9
Colon excluding rectumC18.0 - C18.9, C26.0153.0 - 153.9, 159.0Rectum and rectosigmoidC19.9, C20.9154.0 - 154.1nus, anal canal and anorectumC21.0 - C21.2, C21.8154.2 - 154.3, 154.8iver and intrahepatic bile ductC22.0, C22.1155.0, 155.1, 155.2allbladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Small intestine	C17.0 - C17.9	152.0 - 152.9
Rectum and rectosigmoidC19.9, C20.9154.0 - 154.1nus, anal canal and anorectumC21.0 - C21.2, C21.8154.2 - 154.3, 154.8iver and intrahepatic bile ductC22.0, C22.1155.0, 155.1, 155.2allbladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Colorectal		
nus, anal canal and anorectumC21.0 - C21.2, C21.8154.2 - 154.3, 154.8iver and intrahepatic bile ductC22.0, C22.1155.0, 155.1, 155.2allbladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Colon excluding rectum	C18.0 - C18.9, C26.0	153.0 - 153.9, 159.0
iver and intrahepatic bile ductC22.0, C22.1155.0, 155.1, 155.2allbladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Rectum and rectosigmoid	C19.9, C20.9	154.0 - 154.1
allbladderC23.9156.0ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Anus, anal canal and anorectum	C21.0 - C21.2, C21.8	154.2 - 154.3, 154.8
ther biliaryC24.0 - C24.9156.1 - 156.9ancreasC25.0 - C25.9157.0 - 157.9etroperitoneumC48.0158.0eritoneum, omentum and mesenteryC48.1 - C48.2158.8 - 158.9	Liver and intrahepatic bile duct	C22.0, C22.1	155.0, 155.1, 155.2
ancreas C25.0 - C25.9 157.0 - 157.9 etroperitoneum C48.0 158.0 eritoneum, omentum and mesentery C48.1 - C48.2 158.8 - 158.9	Gallbladder	C23.9	156.0
etroperitoneum C48.0 158.0 eritoneum, omentum and mesentery C48.1 - C48.2 158.8 - 158.9	Other biliary	C24.0 - C24.9	156.1 - 156.9
eritoneum, omentum and mesentery C48.1 - C48.2 158.8 - 158.9	Pancreas	C25.0 - C25.9	157.0 - 157.9
	Retroperitoneum	C48.0	158.0
ther directive organs C268 - C269 C488 1508 - 1509	Peritoneum, omentum and mesentery	C48.1 - C48.2	158.8 - 158.9
uni ingrisure organis	Other digestive organs	C26.8 - C26.9, C48.8	159.8 - 159.9

SITE OF CANCER	ICD-0-2* codes	ICD-9 codes
Respiratory system		
Nasal cavity, middle ear and accessory sinuses	C30.0 - C30.1, C31.0 - C31.9	160.0 - 160.9
Larynx	C32.0 - C32.9	161.0 - 161.9
Lung and bronchus	C34.0 - C34.9	162.2 - 162.9
Pleura	C38.4	163.0 - 163.9
Trachea, mediastinum and other respiratory organs	C33.9, C38.1 - C38.3, C38.8, C39.0, C39.8,C39.9	162.0, 164.2 - 165.9
Bones and joints	C40.0 - C41.9	170.0 - 170.9
Soft tissue (including heart)	C38.0, C47.0 - C47.9, C49.0 - C49.9	171.0 - 171.9, 164.1
Skin (excluding basal and squamous)		
Melanomas of the skin	C44.0 - C44.9 (histologic types 8720 - 8790 only)	172.0 - 172.9
Other non-epithelial skin	C44.0 - C44.9 (excluding histologic types 8000 - 8004, 8010 - 8012, 8070 - 8076, 8090 - 8096, 8720 - 8790 and 9590 - 9989)	173.0 - 173.9
Breast	C50.0 - C50.9	174.0 - 174.9, 175
Female genital system		
Cervix uteri	C53.0 - C53.9	180.0 - 180.9
Corpus uterus and uterus NOS	C54.0 - C54.9, C55.9	179, 182.0 - 182.1, 182.8
Ovary	C56.9	183.0
Vagina	C52.9	184.0
Vulva	C51.0 - C51.9	184.1 - 184.4
Other female genital organs	C57.0 - C57.9, C58.9	181, 183.2 - 183.9, 184.8, 184.9
Male genital system		
Prostate	C61.9	185
Testis	C62.0 - C62.9	186.0 - 186.9
Penis	C60.0 - C60.9	187.1 - 187.4
Other male genital organs	C63.0 - C63.9	187.5 - 187.9

SITE OF CANCER	ICD-0-2* codes	ICD-9 codes
Urinary system		
Urinary bladder	C67.0 - C67.9	188.0 - 188.9
Kidney and renal pelvis	C64.9, C65.9	189.0, 189.1
Ureter	C66.9	189.2
Other urinary organs	C68.0 - C68.9	189.3 - 189.4, 189.8 - 189.9
Eye and orbit	C69.0 - C69.9	190.0 - 190.9
Brain and other nervous system		
Brain	C71.0 - C71.9 (excluding histologic types 9530 - 9539)	191.0 - 191.9
Other nervous system	C71.0 - C71.9 (histologic types 9530 - 9539 only), C70.0 - C70.9, C72.0 - C72.9	192.0 - 192.3, 192.8 - 192.9
Endocrine system		
Thyroid	C73.9	193
Other endocrine (including thymus)	C37.9, C74.0 - C74.9, C75.0 - C75.9	164.0, 194.0 - 194.9
Lymphomas		
Hodgkin's disease	Histologic types 9650 - 9667 only	201.0 - 201.9
Non-Hodgkin's lymphomas	Histologic types 9590 - 9595, 9670 - 9714 only	200.0 - 200.8, 202.0 - 202.2, 202.8 - 202.9
Multiple myeloma	Histologic types 9731 - 9732 only	203.0, 203.2 - 203.8
Leukemias		
Lymphocytic		
Acute lymphocytic	Histologic type 9821	204.0
Chronic lymphocytic	Histologic type 9823	204.1
Other lymphocytic	Histologic types 9820, 9822, 9824, 9825, 9826	204.2 - 204.9
Granulocytic (myeloid)		
Acute granulocytic	Histologic types 9861, 9867	205.0
Chronic granulocytic	Histologic types 9863, 9868	205.1
Other granulocytic	Histologic types 9860, 9862, 9864, 9866	205.2 - 205.9

.8, 208.2- 208.9
3.0 - 196.9 ,
2.5 - 202.6
3

*Unless otherwise stated, all groupings include only invasive cancers (behavior 3) and exclude histologic types 9590 - 9989. Adapted from Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review, 1973 - 1995.

APPENDIX II

1970 United States Standard Million Populations, by Age

Age	United States Standard Million Population, 1970
All Ages	1,000,000
<5	84,416
5-9	98,204
10-14	102,304
15-19	93,845
20-24	80,561
25-29	66,320
30-34	56,249
35-39	54,656
40-44	58,958
45-49	59,622
50-54	54,643
55-59	49,077
60-64	42,403
65-69	34,406
70-74	26,789
75-79	18,871
80-84	11,241
85+	7,435

APPENDIX III

Alaska's 1996 Population

Population estimates used in this report are provided by the Alaska Department of Labor, Research and Analysis Section, Demographics Unit (revised May 1999).

AGE GROUP	TOTAL	MALE	FEMALE
0-4	52,800	26,872	25,928
5-9	56,902	29,137	27,765
10-14	53,652	27,573	26,079
15-19	44,391	23,187	21,204
20-24	32,507	16,572	15,935
25-29	43,104	23,773	19,331
30-34	53,724	28,354	25,370
35-39	61,128	31,540	29,588
40-44	59,002	30,738	28,264
45-49	49,013	26,546	22,467
50-54	32,127	17,391	14,736
55-59	21,326	11,539	9,787
60-64	14,775	7,724	7,051
65-69	11,660	5,901	5,759
70-74	8,670	4,177	4,493
75-79	5,476	2,483	2,993
80-84	2,883	1,209	1,674
85+	1,826	646	1,180
TOTAL	604,966	315,362	289,604

This publication was produced by the Department of Health and Social Services, Division of Public Health, Section of Epidemiology, in order to provide information which may assist in the development of cancer prevention and control programs.